



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT 2025



PHRAMONGKUTKLAO HOSPITAL

ARMY MEDICAL DEPARTMENT
MINISTRY OF DEFENCE
THAILAND

PHRAMONGKUTKLAO HOSPITAL

EXCELLENT CENTER OF CANCER CARE

2025



Title

Phramongkutkiao Hospital Cancer Registry
Report 2025

Editonal Board

Naiyarat Prasongsook, M.D.

Chairman of cancer Registry Committee,
Chairman Excellent Center of Cancer Care.

Kritsada Srithanaphakarangkul, M.D.

Chairman of Cancer of the Data
Information committee

Published by

Clinical Epidemiology Unit and Oncology
Department,

Phramongkutkiao Hospital



315 Chalermprakiet Building, Ratchawithi Road,
Ratchathewi District, Thung Phaya Thai
Subdistrict. Bangkok 10400

Tel. : 02763 3047

Published

2026

Edition

Eighteenth

Physical

77 pages



EXCELLENT CENTER OF CANCER CARE

HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

Phramongkutklo Hospital
Royal Thai Army Medical Department
Ministry of Defence
Bangkok, Thailand

Edited By
Y. Tanapat and K. Srithanaphakarangkul

Edition : December 2025

MESSAGE FROM DIRECTOR OF PHRAMONGKUTKLAO HOSPITAL



The Phramongkutklo Hospital is proud to present the Cancer Registry Report 2025. The report collects information on all new cancer cases. Data collected include the clinical characteristics of the cancer (site, histology, behavior, grade, extent of disease) and treatment details on the cancer patient. The registry has a comprehensive quality assurance program in place to ensure that the data are complete, accurate and timely.

I would like to thank all our collaborators for their dedication in providing data presented in this volume. I would like to express my gratitude to the devoted staffs of cancer registry in all cancer units for the immense amount of work that has been done in preparation of the statistics and graphics for this volume.

A handwritten signature in black ink, reading "Narong Bhakdeesoopapol".

Narong Bhakdeesoopapol, M.D., Maj.Gen.
Director General of Phramongkutklo Hospital
Dean of Phramongkutklo College of Medicine






INTRODUCTION

The Phramongkutklao Hospital Cancer Registry Report 2025 is a hospital-based cancer registry of new cancer patients initially diagnosed or initially treated at Phramongkutklao Cancer Center from January 1, 2025, to December 31, 2025. All new cancer patients registered during the mentioned period were treated at the various Cancer Units under The Excellent center of Cancer Care, Phramongkutklao Hospital. Patients were either primarily diagnosed or referred from army hospitals (under supervision of the Royal Thai Army Medical Department) as well as public and private hospitals. The objective of this is to report new cancer patients regarding method of diagnosis, pathological types, staging, behavior, grading, extension, and primary treatment modalities. Phramongkutklao Hospital has initiated a hospital cancer registry system based on the existing hospital data management system since 2009. This system has enabled physicians and nurses taking care of cancer patients to update patient information on the cancer registry at Cancer Units on a real-time basis. Thus, information obtained can be corrected and updated by persons in charge of patient care at the time of the patient's hospital visit. This process should contribute to the validity of information in the Cancer Registry.

This Cancer Registry Report would not be possible without the dedicated input of data from the staff of the Cancer Clinics and the Cancer Units from different departments at Phramongkutklao Cancer Center.



Assist. Prof. Naiyarat Prasongsook, M.D., M.S., COL.
Chairman Cancer Registry Committee
Phramongkutklao Cancer Center

EXCELLENT CENTER OF CANCER CARE

PHRAMONGKUTKLAO HOSPITAL

1.	Maj.Gen. Surapong	Supaporn	Consultant
2.	Maj.Gen. Sukchai	Satthaporn	Consultant
3.	Col. Kasan	Seetalarom	Consultant
4.	Col. Rachata	Lumkul	Consultant
5.	Col.Chanchai	Traivaree	Consultant
6.	Col. Naiyarat	Prasongsook	Chairman of Administration Committee
7.	Col. Siriwimon	Saichaemchan	Vice Chairman of Administration Committee
8.	Lt.Col. Chonlada	Laoruagroj	Member
9.	Col. Jarey	Ketsirichai	Member
10.	Col. Vana	Sangsasri	Member
11.	Col. Wichitra	Asanprakit	Member
12.	Lt.Col. Sittichoke	Watcharamasbonkkot	Member
13.	Col. Nattapong	Sermasukcharoenchai	Member
14.	Col. Chinakrit	Boonya-Ussadorn	Member
15.	Col.Satit	Siriboonrid	Member
16.	Col. Khunthong	Peechatanan	Member
17.	Col. Sirinthip	Songwutwichai	Member
18.	Col.Chalineee	Monserenusorn	Member
19.	Col. Kritsanamon	Rittiluechai	Member
20.	Col. Wacharaporn	Bourchom	Member
21.	Col. Jariya	Ketkaeo	Member



EXCELLENT CENTER OF CANCER CARE PHRAMONGKUTKLAO HOSPITAL

22.	Lt.Col. Supicha	Wongphun	Member
23.	Lt.Col. Rapeeporn	Kanchanapachana	Member
24.	Lt. Col. Anchalee	Phetwong	Member
25.	Maj. Worachat	Phonpho	Member
26.	Maj. Jarearnjit	Phavirunsiri	Member
27.	Maj. Chetsuda	Khwankorn	Member
28.	Maj. Weerawan	Kaewsai	Member
29.	Maj. Sunisa	Chimcheua	Member
30.	Maj. Intira	Pengpinit	Member
31.	Maj. Waraporn	Baikwang	Member
32.	Capt. Sutipat	Pairojboriboon	Member
33.	Capt. Chatchanin	Ajalanond	Member
34.	Capt. Pitchaya	Sakyanun	Member
35.	Capt. Patcharaporn	Liamsuwan	Member
36.	Capt. Sasimaporn	Kongsakul	Member
37.	Capt. Phanphat	Itthithaveekit	Member
38.	Lt. Tawasapon	Thambamroong	Member and Secretary
39.	Mr. Yannawut	Phurahong	Assistant Secretary

CANCER REGISTRY STAFF

1.	Miss Rungthip	Boonyai	B.Com. (Computer)
2.	Miss Chawanphat	Udomphon	B.Sc. (Statistics)



TABLE OF CONTENTS

Title		
List of tables:		Page
Table 1	Distribution of new cancer patients by gender: 2025	1
Table 2	Number of all new patients: 2013-2024	2
Table 3	Ten leading primary sites of new cancer patients by gender: 2025	3
Table 4	Ten leading primary sites of new cancer patients in male: 2025	4
Table 5	Ten leading primary sites of new cancer patients in female: 2025	5
Table 6	Distribution of new cancer patients by age group and gender: 2025	6
Table 7	Distribution of new cancer patients by stage and gender: 2025	7
Table 8	Distribution of new cancer patients by grade and gender : 2025	8
Table 9	Distribution of new cancer patients by extension and gender: 2025	9
Table 10	Distribution of new cancer patients by method and gender: 2025	10
Table 11	Distribution of new cancer patients by treatment modalities and gender: 2025	11
Table 12	Distribution of new cancer patients by treatment unit and gender: 2025	15
Table 13	Distribution of new cancer patients by status 2025	16
Table 14	Distribution of new cancer patients by follow up status and gender 2025	16
Table 15	Distribution of new military personnel cancer patients by age group and gender: 2025	17
Table 16	Distribution of new cancer patients by rank and gender: 2025	18
Table 17	Distribution of new childhood cancer patients (age 0-19) by age group and gender: 2025	19
Table 18	Distribution of new childhood cancer patients (age 0-19) by primary sites: 2025	19
Table 19	Distribution of new childhood cancer patients (age 0-19) by treatment modalities and gender: 2025	20
Table 20	Distribution of new childhood cancer patients (age 0-19) by method and gender: 2025	20
Table 21	Distribution of new childhood cancer patients (age 0-19) by type of extension and gender: 2025	21
Table 22	Distribution of new childhood cancer patients (age 0-19) by follow up and gender: 2025	21
Table 23	Number of new cancer patient stage and gender: 2025	22

TABLE OF CONTENTS

Title		
List of tables:		Page
Description of the leading site of cancers ordinal 1-3		
1. Colon and rectum cancer		
Table 24	Trend of colon and rectum cancer in Phramongkutklao hospital: 2013-2024	28
Table 25	Distribution of new colon and rectum cancer patients by age group and gender: 2025	29
Table 26	Distribution of new colon and rectum cancer patients by stage and gender: 2025	30
Table 27	Distribution of new colon and rectum cancer patients by method and gender: 2025	31
Table 28	Distribution of new colon and rectum cancer patients by extension and gender: 2025	31
Table 29	Distribution of new colon and rectum cancer patients by treatment modalities and gender: 2025	32
Table 30	Distribution of new colon and rectum cancer patients by follow up status and gender: 2025	33
2. Breast cancer		
Table 31	Trend of breast cancer in Phramongkutklao hospital: 2013-2024	34
Table 32	Distribution of new breast cancer patients by age group and gender: 2025	35
Table 33	Distribution of new breast cancer patients by stage and gender: 2025	36
Table 34	Distribution of new breast cancer patients by method and gender: 2025	37
Table 35	Distribution of new breast cancer patients by extension and gender: 2025	37
Table 36	Distribution of new breast cancer patients by treatment modalities and gender: 2025	38
Table 37	Distribution of new breast cancer patients by follow up status and gender: 2025	39
3. Bronchus, and lung cancer		
Table 38	Trend of bronchus, and lung cancer in Phramongkutklao hospital: 2013-2024	40
Table 39	Distribution of new bronchus and lung cancer patients by age group and gender: 2025	41
Table 40	Distribution of new bronchus and lung cancer patients by stage and gender: 2025	42
Table 41	Distribution of new bronchus and lung cancer patients by method and gender: 2025	43
Table 42	Distribution of new bronchus and lung cancer patients by extension and gender: 2025	43
Table 43	Distribution of new bronchus and lung cancer patients by treatment modalities and gender: 2025	44
Table 44	Distribution of new bronchus, and lung cancer patients by follow up status and gender: 2025	44

TABLE OF CONTENTS

Title		
List of tables:		Page
Description of the leading site of cancers ordinal 4-6		
4. Prostate gland cancer		
Table 45	Distribution of new prostate gland cancer patients by age group and gender : 2025	45
Table 46	Distribution of new prostate gland cancer patients by stage and gender : 2025	46
Table 47	Distribution of new prostate gland cancer patients by method and gender : 2025	47
Table 48	Distribution of new prostate gland cancer patients by extension and gender : 2025	47
Table 49	Distribution of new prostate gland cancer patients by treatment modalities and gender : 2025	48
Table 50	Distribution of new prostate gland cancer patients by follow up status and gender : 2025	48
5. Thyroid cancer		
Table 51	Distribution of new thyroid cancer patients by age group and gender: 2025	49
Table 52	Distribution of new thyroid cancer patients by stage and gender: 2025	50
Table 53	Distribution of new thyroid cancer patients by method and gender: 2025	51
Table 54	Distribution of new thyroid cancer patients by extension and gender: 2025	51
Table 55	Distribution of new thyroid cancer patients by treatment modalities and gender: 2025	55
Table 56	Distribution of new thyroid cancer patients by follow up status and gender: 2025	55
6. Liver and intrahepatic bile ducts cancer		
Table 57	Distribution of new Liver and intrahepatic bile ducts cancer patients by age group and gender: 2025	53
Table 58	Distribution of new Liver and intrahepatic bile ducts cancer patients by stage and gender: 2025	54
Table 59	Distribution of new Liver and intrahepatic bile ducts cancer patients by method and gender: 2025	55
Table 60	Distribution of new Liver and intrahepatic bile ducts cancer patients by extension and gender: 2025	55
Table 61	Distribution of new Liver and intrahepatic bile ducts cancer patients by treatment modalities and gender: 2025	56
Table 62	Distribution of new Liver and intrahepatic bile ducts cancer patients by follow up status and gender: 2025	56

TABLE OF CONTENTS

Title		
List of tables:		Page
Number of cases by age-group in sex		
Table 63	Distribution of new cancer in male by age - group: 2025	57
Table 64	Distribution of new cancer in female by age - group: 2025	58
Distribution of new cancer in by morphology and site: 2025		
Table 65	Distribution of new cancer patients by morphology and site: 2025	59
Distribution of new cancer patients: 2021-2025		
Table 66	Number of new cancer patients: 2021-2025	73
Table 67	Distribution of new cancer patients by follow up and gender: 2021-2025	73
Table 68	The leading primary sites of new cancer by gender: 2021-2025	74
Table 69	The leading primary sites of new cancer by follow up and gender: 2021-2025	74
Table 70	The 5 Years survival time (median) top 6 by gender in 2021 - 2025	75



FIGURE OF CONTENTS

Title		
List of figures:		Page
Figure 1	All new cancer cases in Phramongkutklao hospital :2013-2024	1
Figure 2	Trend of number of all new cancer patients by gender :2013-2024	2
Figure 3	Ten leading primary sites of new cancer patients by gender: 2025	3
Figure 4	Ten leading primary sites of new cancer patients in male: 2025	4
Figure 5	Ten leading primary sites of new cancer patients in female: 2025	5
Figure 6	Distribution of new cancer patients by age group and gender: 2025	6
Figure 7	Distribution of new cancer patients by stage and gender: 2025	7
Figure 8	Distribution of new cancer patients by grade and gender: 2025	8
Figure 9	Distribution of new cancer patients by extension and gender: 2025	9
Figure 10	Distribution of new cancer patients by method and gender: 2025	10
Figure 11	Distribution of new cancer patients by treatment unit and gender: 2025	15
Figure 12	Distribution of new cancer patients by follow up status: 2025	16
Figure 13	Distribution of new military personnel cancer patients by age group and gender: 2025	17
Figure 14	Distribution of new cancer patients by rank and gender: 2025	18



FIGURE OF CONTENTS

Title		
List of figures:		Page
Description of the leading site of cancers ordinal 1-3		
1. Colon and rectum cancer		
Figure 15	Distribution of new colon and rectum cancer patients by age group and gender: 2025	29
Figure 16	Distribution of new colon and rectum cancer patients by stage and gender: 2025	30
Figure 17	Distribution of new colon and rectum cancer patients by extension and gender: 2025	31
2. Breast cancer		
Figure 18	Distribution of new breast cancer patients by age group and gender: 2025	35
Figure 19	Distribution of new breast cancer patients by stage and gender: 2025	36
Figure 20	Distribution of new breast cancer patients by extension and gender: 2025	37
3. Bronchus, and lung cancer		
Figure 21	Distribution of new bronchus and lung cancer patients by age group and gender: 2025	41
Figure 22	Distribution of new bronchus and lung cancer patients by stage and gender: 2025	42
Figure 23	Distribution of new bronchus and lung cancer patients by extension and gender: 2025	43
4. Prostate gland cancer		
Figure 24	Distribution of new prostate gland cancer patients by age group and gender: 2025	45
Figure 25	Distribution of new prostate gland cancer patients by stage and gender: 2025	46
Figure 26	Distribution of new prostate gland cancer patients by extension and gender: 2025	47
5. Thyroid cancer		
Figure 27	Distribution of new thyroid cancer patients by age group and gender: 2025	49
Figure 28	Distribution of new thyroid cancer patients by stage and gender: 2025	50
Figure 29	Distribution of new thyroid cancer patients by extension and gender: 2025	51
6. Liver and intrahepatic bile ducts cancer		
Figure 30	Distribution of new Liver and intrahepatic bile ducts cancer patients by age group and gender: 2025	53
Figure 31	Distribution of new Liver and intrahepatic bile ducts cancer patients by stage and gender: 2025	54
Figure 32	Distribution of new Liver and intrahepatic bile ducts cancer patients by extension and gender: 2025	55

FIGURE OF CONTENTS

Title		
List of tables:		Page
Number of cases by age-group in sex		
Distribution of the 60-month survival rate of cancers in : 2021 – 2025		
Figure 33	The 5 Years survival rate (top 6) in 2021 – 2025	75
Figure 34	The 5 Years survival rate (top 6) by male in 20201– 2025	76
Figure 35	The 5 Years survival rate (top 6) by Female in 2021 – 2025	77




2025

HOSPITAL-BASED CANCER REGISTRY
ANNUAL REPORT



TABLE 1 DISTRIBUTION OF NEW CANCER PATIENTS BY GENDER : 2025	
Type of patients	Number of cases
Total new hospital patients	41,522 (100.00%)
Total new cancer patients	1,736 (4.18%)
Gender distribution of cancer	
• Male	838 (2.02%)
• Female	898 (2.16%)

FIGURE 1: ALL NEW CANCER CASE IN PHRAMONGKUTKLOA HOSPITAL: 2014 – 2025





HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

TABLE 2NUMBER OF ALL NEW PATIENTS : 2014– 2025							
Years	New patient	New cancer case	Case	Male		Female	
	Number	Number	Percent	Number	Percent	Number	Percent
2557 (2014)	68,306	1,856	2.72	947	1.39	909	1.33
2558 (2015)	55,484	1,536	2.77	801	1.44	735	1.32
2559 (2016)	59,191	1,771	2.99	881	1.49	890	1.50
2560 (2017)	58,320	1,539	2.64	779	1.34	760	1.30
2561 (2018)	55,771	1,666	2.99	886	1.59	780	1.40
2562 (2019)	57,049	1,720	3.01	885	1.55	835	1.46
2563 (2020)	42,412	1,608	3.79	800	1.89	808	1.91
2564 (2021)	46,210	1,526	3.30	771	1.67	755	1.63
2565 (2022)	47,768	1,702	3.56	822	1.72	880	1.84
2566 (2023)	41,671	1,825	4.38	912	2.19	913	2.19
2567 (2024)	44,300	1,924	4.34	944	2.13	980	2.21
2568 (2025)	41,522	1,736	4.18	838	2.02	898	2.16

FIGURE 2: TREND OF NUMBER OF ALL NEW PATIENTS BY GENDER: 2014 – 2025







TABLE 3 TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS BY GENDER : 2025							
Ordinal	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
1	Colon & Rectum	144	17.2	101	11.2	245	14.1
2	Breast	1	0.1	186	20.7	187	10.8
3	Bronchus & Lung	96	11.5	82	9.1	178	10.3
4	Prostate gland	117	14.0	0	0.0	117	6.7
5	Thyroid	22	2.6	84	9.4	106	6.1
6	Liver & intrahepatic bile ducts	67	8.0	26	2.9	93	5.4
7	Digestive organ	56	6.7	30	3.3	86	5.0
8	Non-Hodgkin's lymphoma	43	5.1	37	4.1	80	4.6
9	Endometrium	0	0.0	68	7.6	68	3.9
10	Cervix	0	0.0	62	6.9	62	3.6
Others		292	34.8	222	24.8	514	29.5
Total		838	100.0	898	100.0	1736	100.0

FIGURE 3: TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS BY GENDER: 2025





HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

TABLE 4	TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN MALE : 2025		
Ordinal	Primary site	Number	Percent
1	Colon & Rectum	144	17.2
2	Prostate gland	117	14.0
3	Bronchus & Lung	96	11.5
4	Liver & intrahepatic bile ducts	67	8.0
5	Digestive organ	56	6.7
6	Non-Hodgkin's lymphoma	43	5.1
7	Leukemia	35	4.2
8	Malignant neoplasm of lip, oral cavity & pharynx	33	3.9
9	Skin	31	3.7
10	Kidney, renal pelvis & ureter	27	3.2
Others		189	22.6
Total		838	100.0

FIGURE 4: TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN MALE: 2025







TABLE 5	TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN FEMALE : 2025		
Ordinal	Primary site	Number	Percent
1	Breast	186	20.7
2	Colon & Rectum	101	11.2
3	Thyroid	84	9.4
4	Bronchus & Lung	82	9.1
5	Endometrium	68	7.6
6	Cervix	62	6.9
7	Ovary	55	6.1
8	Non-Hodgkin's lymphoma	37	4.1
9	Digestive organ	30	3.3
10	Leukemia	26	2.9
Others		167	18.6
Total		898	100.0

FIGURE 5: TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN FEMALE: 2025





HOSPITAL-BASED CANCER REGISTRY

2025

ANNUAL REPORT

TABLE 6	DISTRIBUTION OF NEW CANCER PATIENTS BY AGE GROUP AND GENDER : 2025					
Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
0 – 4	5	0.6	1	0.1	6	0.3
5 – 9	0	0.0	2	0.2	2	0.1
10 – 14	1	0.1	3	0.3	4	0.2
15 – 19	6	0.7	1	0.1	7	0.4
20 – 24	14	1.7	6	0.7	20	1.2
25 – 29	18	2.1	14	1.6	32	1.8
30 – 34	13	1.6	29	3.2	42	2.4
35 – 39	20	2.4	40	4.5	60	3.5
40 – 44	26	3.1	62	6.9	88	5.1
45 – 49	47	5.6	89	9.9	136	7.8
50 – 54	75	8.9	97	10.8	172	9.9
55 – 59	85	10.1	87	9.7	172	9.9
60 – 64	114	13.6	124	13.8	238	13.7
65 – 69	111	13.2	90	10.0	201	11.6
70 – 74	101	12.1	92	10.2	193	11.1
75 – 79	99	11.8	71	7.9	170	9.8
80 – 84	57	6.8	44	4.9	101	5.8
85 +	46	5.5	46	5.1	92	5.3
Total	838	100.0	898	100.0	1736	100.0

Majority of cases

FIGURE 6: DISTRIBUTION OF NEW CANCER PATIENTS BY AGE GROUP AND GENDER: 2025







TABLE 7	DISTRIBUTION OF NEW CANCER PATIENTS BY STAGE AND GENDER : 2025					
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	161	19.2	226	25.2	387	22.3
Stage II	156	18.6	214	23.8	370	21.3
Stage III	195	23.3	172	19.2	367	21.1
Stage IV	289	34.5	252	28.1	541	31.2
No stage	35	4.2	30	3.3	65	3.7
Unknown	2	0.2	4	0.4	6	0.3
Total	838	100.0	898	100.0	1736	100.0

*No stage: manual system including leukemia and brain

FIGURE 7: DISTRIBUTION OF NEW CANCER PATIENTS BY STAGE AND GENDER: 2025





HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

TABLE 8		DISTRIBUTION OF NEW CANCER PATIENTS BY GRADE AND GENDER : 2025				
Grade	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Well differentiated	107	12.8	143	15.9	250	14.4
Moderately differentiated	151	18.0	203	22.6	354	20.4
Poorly differentiated	189	22.6	182	20.3	371	21.4
Undifferentiated	38	4.5	7	0.8	45	2.6
T – Cell	57	6.8	43	4.8	100	5.8
B – Cell	52	6.2	38	4.2	90	5.2
Differentiated not Determined	244	29.1	282	31.4	526	30.3
Total	838	100.0	898	100.0	1736	100.0

FIGURE 8: DISTRIBUTION OF NEW CANCER PATIENTS BY GRADE AND GENDER: 2025







TABLE 9		DISTRIBUTION OF NEW CANCER PATIENTS BY EXTENSION AND GENDER : 2025				
Extend	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	512	61.1	554	61.7	1066	61.4
Regional lymph nodes	109	13.0	127	14.1	236	13.6
Distant metastasis	217	25.9	217	24.2	434	25.0
Total	838	100.0	898	100.0	1736	100.0

FIGURE 9: DISTRIBUTION OF NEW CANCER PATIENTS BY EXTENSION AND GENDER: 2025






HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	6	0.7	17	1.9	23	1.3
Histopathology or Cytology	684	81.6	786	87.5	1470	84.7
Endoscopy	17	2.0	6	0.7	23	1.3
Bone marrow examination	102	12.2	79	8.8	181	10.4
Tumor marker	29	3.5	10	1.1	39	2.2
Total	838	100.0	898	100.0	1736	100.0

FIGURE 10: DISTRIBUTION OF NEW CANCER PATIENTS BY METHOD AND GENDER: 2025





Treatment modality	DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2025					
	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	241	28.8	279	31.1	520	30.0
Radiation	34	4.1	48	5.3	82	4.7
Chemotherapy	107	12.8	123	13.7	230	13.2
Hormone	0	0.0	5	0.6	5	0.3
Immunotherapy	18	2.1	13	1.4	31	1.8
Interventional	22	2.6	6	0.7	28	1.6
Targeted therapy	5	0.6	5	0.6	10	0.6
Stem cell transplantation	4	0.5	2	0.2	6	0.3
Surgery & Radiotherapy	12	1.4	35	3.9	47	2.7
Surgery & Chemotherapy	85	10.1	135	15.0	220	12.7
Surgery & Hormone	0	0.0	2	0.2	2	0.1
Surgery & Interventional	2	0.2	1	0.1	3	0.2
Surgery & Targeted therapy	0	0.0	3	0.3	3	0.2
Radiotherapy & Chemotherapy	13	1.6	13	1.4	26	1.5
Radiotherapy & Immunotherapy	1	0.1	0	0.0	1	0.1
Radiation & Targeted therapy	2	0.2	1	0.1	3	0.2



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

TABLE 11	DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2025					
	Male		Female		Total	
Treatment modality	Number	Percent	Number	Percent	Number	Percent
Chemotherapy & Immunotherapy	41	4.9	36	4.0	77	4.4
Chemotherapy & Interventional	14	1.7	7	0.8	21	1.2
Chemotherapy & Targeted therapy	4	0.5	8	0.9	12	0.7
Hormone & Immunotherapy	0	0.0	1	0.1	1	0.1
Chemotherapy & Stem cell transplantation	0	0.0	1	0.1	1	0.1
Immunotherapy & Stem cell transplantation	1	0.1	1	0.1	2	0.1
Surgery, Radiotherapy & Chemotherapy	8	1.0	13	1.4	21	1.2
Surgery, Radiotherapy & Immunotherapy	1	0.1	0	0.0	1	0.1
Surgery, Radiotherapy & Targeted therapy	1	0.1	0	0.0	1	0.1
Surgery, Chemotherapy & Immunotherapy	6	0.7	5	0.6	11	0.6
Surgery, Chemotherapy & Interventional	3	0.4	1	0.1	4	0.2
Surgery, Chemotherapy & Targeted therapy	1	0.1	6	0.7	7	0.4
Surgery, Immunotherapy & Targeted therapy	0	0.0	1	0.1	1	0.1
Radiotherapy, Chemotherapy & Immunotherapy	1	0.1	2	0.2	3	0.2
Radiotherapy, Chemotherapy & Targeted therapy	2	0.2	1	0.1	3	0.2
Chemotherapy, Hormone & Immunotherapy	0	0.0	1	0.1	1	0.1



Treatment modality	DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2025					
	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Chemotherapy, Immunotherapy & Interventional	0	0.0	1	0.1	1	0.1
Chemotherapy, Immunotherapy & Targeted therapy	4	0.5	1	0.1	5	0.3
Chemotherapy, Immunotherapy & Stem cell transplantation	1	0.1	5	0.6	6	0.3
Surgery, Radiotherapy, Chemotherapy & Immunotherapy	0	0.0	1	0.1	1	0.1
Surgery, Radiotherapy, Chemotherapy & Targeted therapy	0	0.0	2	0.2	2	0.1
Surgery, Chemotherapy, Hormone & Immunotherapy	0	0.0	1	0.1	1	0.1
Surgery, Chemotherapy, Hormone & Targeted therapy	1	0.1	0	0.0	1	0.1
Surgery, Chemotherapy, Immunotherapy & Targeted therapy	0	0.0	1	0.1	1	0.1



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiotherapy, Chemotherapy, Immunotherapy & Targeted therapy	0	0.0	1	0.1	1	0.1
Radiotherapy, Hormone, Immunotherapy & Targeted therapy	0	0.0	1	0.1	1	0.1
Counseling	203	24.2	129	14.4	332	19.1
Total	838	100.0	898	100.0	1736	100.0





Treatment unit	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Department of Surgery	400	47.7	319	35.5	719	41.4
Department of Medicine	322	38.4	265	29.5	587	33.8
Department of Obstetrics and Gynecology	0	0.0	184	20.5	184	10.6
Department of Ear, Nose and Throat	83	9.9	79	8.8	162	9.3
Department of Radiology	17	2.0	34	3.8	51	2.9
Department of Orthopedics	9	1.1	13	1.4	22	1.3
Department of Pediatrics	7	0.8	4	0.4	11	0.6
Total	838	100.0	898	100.0	1736	100.0

FIGURE 11: DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT UNIT AND GENDER: 2025






TABLE 13	DISTRIBUTION OF NEW CANCER PATIENTS BY STATUS AND GENDER : 2025					
Status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Military	232	27.7	55	6.1	287	16.5
Civilian	606	72.3	843	93.9	1449	83.5
Total	838	100.0	898	100.0	1736	100.0

TABLE 14	DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP STATUS AND GENDER : 2025					
Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	649	77.4	755	84.1	1404	80.9
Deaths	189	22.6	143	15.9	332	19.1
Total	838	100.0	898	100.0	1736	100.0

Survey: 1 May 2026

FIGURE 12: DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP STATUS AND GENDER : 2025







TABLE 15 DISTRIBUTION OF NEW MILITARY PERSONNEL CANCER PATIENTS BY AGE GROUP AND GENDER : 2025						
Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
0 – 19	0	0.0	0	0.0	0	0.0
20 – 24	2	0.9	0	0.0	2	0.7
25 – 29	3	1.3	1	1.8	4	1.4
30 – 34	1	0.4	0	0.0	1	0.3
35 – 39	2	0.9	3	5.5	5	1.7
40 – 44	4	1.7	4	7.3	8	2.8
45 – 49	5	2.2	3	5.5	8	2.8
50 – 54	7	3.0	8	14.5	15	5.2
55 – 59	18	7.8	11	20.0	29	10.1
60 – 64	43	18.5	7	12.7	50	17.4
65 – 69	37	15.9	4	7.3	41	14.3
70 – 74	31	13.4	6	10.9	37	12.9
75 – 79	38	16.4	4	7.3	42	14.6
80 – 84	20	8.6	2	3.6	22	7.7
85 +	21	9.1	2	0.2	23	8.0
Total	232	100.0	55	96.6	287	100.0

Majority of cases

FIGURE 13: DISTRIBUTION OF NEW MILITARY PERSONNEL CANCER PATIENTS BY AGE GROUP AND GENDER: 2025





HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

TABLE 16		DISTRIBUTION OF NEW CANCER PATIENTS BY RANK AND GENDER : 2025				
Rank	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Major General – General	59	25.4	8	14.5	67	23.3
Major – Colonel	74	31.9	32	58.2	106	36.9
Sub Lieutenant – Captain	58	25.0	5	9.1	63	22.0
Sergeant Major 3 rd - Sergeant Major 1 st	25	10.8	8	14.5	33	11.5
Private 1 st class – Sergeant	14	6.0	2	3.6	16	5.6
Enlisted Soldier	2	0.9	0	0.0	2	0.7
Total	232	100.0	55	100.0	287	100.0

FIGURE 14: DISTRIBUTION OF NEW CANCER PATIENTS BY RANK AND GENDER: 2025






TABLE 17	DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY AGE GROUP AND GENDER : 2025					
Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
0 – 4	5	41.7	1	14.3	6	31.6
5 – 9	0	0.0	2	28.6	2	10.5
10 – 14	1	8.3	3	42.9	4	21.1
15 - 19	6	50.0	1	14.3	7	36.8
Total	12	100.0	7	100.0	19	100.0

TABLE 18	DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY PRIMARY SITES : 2025				
Ordinal	Primary site	Male	Female	Total	
		Number	Number	Number	Percent
1	Leukemia	6	2	8	42.1
2	Non-Hodgkin's lymphoma	0	2	2	10.5
3	Brain	1	0	1	5.3
4	Hodgkin's disease	1	0	1	5.3
5	Kidney, renal pelvis & ureter	1	0	1	5.3
6	Malignant neoplasm of lip, oral cavity & pharynx	1	0	1	5.3
7	Malignant neoplasm of adrenal gland	1	0	1	5.3
8	Thyroid	1	0	1	5.3
9	Bone & articular cartilage	0	1	1	5.3
10	Digestive organ	0	1	1	5.3
11	Ovary	0	1	1	5.3
Total		12	7	19	100.0



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

TABLE 19	DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY TREATMENT MODALITES AND GENDER : 2025					
	Treatment modality	Male		Female		Total
		Number	Percent	Number	Percent	Number Percent
	Surgery	3	25.0	1	14.3	4 21.1
	Chemotherapy	4	33.3	3	42.9	7 36.8
	Immunotherapy	1	8.3	0	0.0	1 5.3
	Surgery & Chemotherapy	1	8.3	1	14.3	2 10.5
	Surgery, Radiotherapy & Chemotherapy	2	16.7	0	0.0	2 10.5
	Radiotherapy, Chemotherapy & Immunotherapy	0	0.0	1	14.3	1 5.3
	Counseling	1	8.3	1	14.3	2 10.5
	Total	12	100.0	7	100.0	19 100.0

TABLE 20	DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY METHOD OF DIAGNOSIS AND GENDER : 2025					
	Method of diagnosis	Male		Female		Total
		Number	Percent	Number	Percent	Number Percent
	Histopathology or Cytology	5	41.7	3	42.9	8 42.1
	Bone marrow	7	58.3	4	57.1	11 57.9
	Total	12	100.0	7	100.0	19 100.0



TABLE 21	DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY TYPE OF EXTENSION AND GENDER : 2025					
	Spreading/Metastasis		Male		Female	
			Number	Percent	Number	Percent
Localized			10	83.3	6	85.7
Regional lymph nodes			1	8.3	0	0.0
Distant metastasis			1	8.3	1	14.3
Total			12	100.0	7	100.0

TABLE 22	DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY FOLLOW UP AND GENDER : 2025					
	Follow up status		Male		Female	
			Number	Percent	Number	Percent
Alive			11	91.7	5	71.4
Deaths			1	8.3	2	28.6
Total			12	100.0	7	100.0

Survey: 1 May 2026





HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

TABLE 23		NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2025							
Site	Sex		Stage						
			I	II	III	IV	No stage	Un known	Total
Bladder	Male		7	5	7	7	-	-	26
	Female		6	5	1	2	-	-	14
	Total	(N)	13	10	8	9	-	-	40
		(%)	32.5	25.0	20.0	22.5	-	-	100.0
Bone & articular cartilage	Male		1	1	2	3	-	-	7
	Female		2	4	3	2	-	-	11
	Total	(N)	3	5	5	5	-	-	18
		(%)	16.7	27.8	27.8	27.8	-	-	100.0
Brain	Male		-	-	-	1	13	-	14
	Female		-	-	-	0	4	-	4
	Total	(N)	-	-	-	1	17	-	18
		(%)	-	-	-	5.6	94.4	-	100.0
Breast	Male		0	0	0	1	-	-	1
	Female		50	71	34	31	-	-	186
	Total	(N)	50	71	34	32	-	-	187
		(%)	26.7	38.0	18.2	17.1	-	-	100.0
Cervix	Male		0	0	0	0	-	-	
	Female		21	19	14	8	-	-	62
	Total	(N)	21	19	14	8	-	-	62
		(%)	33.9	30.6	22.6	12.9	-	-	100.0
Colon & Rectum	Male		20	35	52	37	-	-	144
	Female		11	23	37	30	-	-	101
	Total	(N)	31	58	89	67	-	-	245
		(%)	12.7	23.7	36.3	27.3	-	-	100.0



TABLE 23		NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2025							
Site	Sex		Stage						
			I	II	III	IV	No stage	Un known	Total
Malignant neoplasm of placenta	Male		-	0	0	-	-	-	
	Female		-	1	1	-	-	-	2
	Total	(N)	-	1	1	-	-	-	2
		(%)	-	50.0	50.0	-	-	-	100.0
Hodgkin's disease	Male		-	2	2	4	-	-	8
	Female		-	3	0	0	-	-	3
	Total	(N)	-	5	2	4	-	-	11
		(%)	-	45.5	18.2	36.4	-	-	100.0
Hypopharynx	Male		-	1	4	6	-	-	11
	Female		-	0	0	0	-	-	0
	Total	(N)	-	1	4	6	-	-	11
		(%)	-	9.1	36.4	54.5	-	-	100.0
Malignant neoplasm of respiratory & Intrathoracic organs	Male		6	2	2	11	-	-	21
	Female		2	0	3	1	-	-	6
	Total	(N)	8	2	5	12	-	-	27
		(%)	29.6	7.4	18.5	44.4	-	-	100.0
Kidney, renal pelvis & ureter	Male		8	3	6	10	-	-	27
	Female		3	5	1	5	-	-	14
	Total	(N)	11	8	7	15	-	-	41
		(%)	26.8	19.5	17.1	36.6	-	-	100.0
Leukemia	Male		1	-	6	4	22	2	35
	Female		0	-	1	2	22	1	26
	Total	(N)	1	-	7	6	44	3	61
		(%)	1.6	-	11.5	9.8	72.1	4.9	100.0



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

TABLE 23		NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2025							
Site	Sex		Stage						
			I	II	III	IV	No stage	Un known	Total
Malignant neoplasm of lip, oral cavity & pharynx	Male		0	6	9	18	-	-	33
	Female		3	5	3	9	-	-	20
	Total	(N)	3	11	12	27	-	-	53
		(%)	5.7	20.8	22.6	50.9	-	-	100.0
Malignant neoplasm of mesothelial & soft tissue	Male		3	0	7	9	-	-	19
	Female		2	3	2	1	-	-	8
	Total	(N)	5	3	9	10	-	-	27
		(%)	18.5	11.1	33.3	37.0	-	-	100.0
Multiple myeloma & malignant plasma cell neoplasms	Male		4	5	8	3	-	-	20
	Female		2	2	9	2	-	-	15
	Total	(N)	6	7	17	5	-	-	35
		(%)	17.1	20.0	48.6	14.3	-	-	100.0
Non-Hodgkin's lymphoma	Male		8	8	3	24	0	-	43
	Female		7	2	7	19	2	-	37
	Total	(N)	15	10	10	43	2	-	80
		(%)	18.8	12.5	12.5	53.8	2.5	-	100.0
Digestive organ	Male		4	12	19	21	-	-	56
	Female		2	7	7	14	-	-	30
	Total	(N)	6	19	26	35	-	-	86
		(%)	7.0	22.1	30.2	40.7	-	-	100.0
Malignant neoplasm of other endocrine glands and relate structures	Male		1	2	1	2	0	-	6
	Female		0	0	0	1	2	-	3
	Total	(N)	1	2	1	3	2	-	9
		(%)	11.1	22.2	11.1	33.3	22.2	-	100.0



TABLE 23		NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2025							
Site	Sex		Stage						
			I	II	III	IV	No stage	Un known	Total
Ovary	Male		0	0	0	0	-	0	0
	Female		9	3	12	29	-	2	55
	Total	(N)	9	3	12	29	-	2	55
		(%)	16.4	5.5	21.8	52.7	-	3.6	100.0
Pancreas	Male		3	2	4	11	-	-	20
	Female		1	2	1	15	-	-	19
	Total	(N)	4	4	5	26	-	-	39
		(%)	10.3	10.3	12.8	66.7	-	-	100.0
Prostate gland	Male		38	34	20	25	-	-	117
	Female		0	0	0	0	-	-	0
	Total	(N)	38	34	20	25	-	-	117
		(%)	32.5	29.1	17.1	21.4	-	-	100.0
Liver & intrahepatic bile ducts	Male		12	15	14	26	-	-	67
	Female		5	9	5	7	-	-	26
	Total	(N)	17	24	19	33	-	-	93
		(%)	18.3	25.8	20.4	35.5	-	-	100.0
Skin	Male		22	2	6	1	-	-	31
	Female		13	4	0	2	-	-	19
	Total	(N)	35	6	6	3	-	-	50
		(%)	70.0	12.0	12.0	6.0	-	-	100.0
Thyroid	Male		8	7	5	2	-	-	22
	Female		44	17	11	12	-	-	84
	Total	(N)	52	24	16	14	-	-	106
		(%)	49.1	22.6	15.1	13.2	-	-	100.0



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

TABLE 23

NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2025

Site	Sex		Stage						
			I	II	III	IV	No stage	Un known	Total
Bronchus & Lung	Male		12	12	15	57	-	0	96
	Female		10	12	8	51	-	1	82
	Total	(N)	22	24	23	108	-	1	178
		(%)	12.4	13.5	12.9	60.7	-	0.6	100.0
Endometrium	Male		0	0	0	0	-	-	0
	Female		33	16	11	8	-	-	68
	Total	(N)	33	16	11	8	-	-	68
		(%)	48.5	23.5	16.2	11.8	-	-	100.0
Malignant neoplasm of ill-defined, secondary & unspecified sites	Male		-	1	-	1	-	-	2
	Female		-	0	-	0	-	-	0
	Total	(N)	-	1	-	1	-	-	2
		(%)	-	50.0	-	50.0	-	-	100.0
Malignant neoplasm of penis	Male		1	-	-	1	-	-	2
	Female		0	-	-	0	-	-	0
	Total	(N)	1	-	-	1	-	-	2
		(%)	50.0	-	-	50.0	-	-	100.0
Eye & Meninges	Male		1	0	-	2	-	-	3
	Female		0	1	-	1	-	-	2
	Total	(N)	1	1	-	3	-	-	5
		(%)	20.0	20.0	-	60.0	-	-	100.0
Malignant neoplasm of testis	Male		1	1	3	2	-	-	7
	Female		0	0	1	0	-	-	1
	Total	(N)	1	1	4	2	-	-	8
		(%)	12.5	12.5	50.0	25.0	-	-	100.0
Total	Male		161	156	195	289	35	2	838
	Female		226	214	172	252	30	4	898
	Total	(N)	387	370	367	541	65	6	1736
		(%)	22.3	21.3	21.1	31.2	3.7	0.3	100.0



DESCRIPTION OF THE LEADING SITES OF CANCERS

COLON & RECTUM 1

BREAST 2

BRONCHUS & LUNG 3

PROSTATE GLAND 4

THYROID 5

LIVER & INTRAHEPATIC BILE DUCTS 6





1

COLON AND RECTUM

CANCER



TABLE 24

TREND OF COLON AND RECTUM CANCER IN PHRAMONGKUTKLAO HOSPITAL : 2014 - 2025

Years	Number of patients		Total
	Male	Female	
2014	130	87	217
2015	120	81	201
2016	140	88	228
2017	102	67	169
2018	104	56	160
2019	132	91	223
2020	107	72	179
2021	117	82	199
2022	140	95	235
2023	147	102	249
2024	125	105	230
2025	144	101	245




COLON AND RECTUM CANCER

TABLE 25	DISTRIBUTION OF COLON AND RECTUM CANCER PATIENTS BY AGE GROUP AND GENDER : 2025					
Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 19	0	0.0	0	0.0	0	0.0
20 – 24	1	0.7	0	0.0	1	0.4
25 – 29	1	0.7	0	0.0	1	0.4
30 – 34	0	0.0	1	1.0	1	0.4
35 – 39	4	2.8	1	1.0	5	2.0
40 – 44	4	2.8	7	6.9	11	4.5
45 – 49	6	4.2	7	6.9	13	5.3
50 – 54	9	6.3	7	6.9	16	6.5
55 – 59	19	13.2	9	8.9	28	11.4
60 – 64	18	12.5	15	14.9	33	13.5
65 – 69	27	18.8	10	9.9	37	15.1
70 – 74	17	11.8	16	15.8	33	13.5
75 – 79	15	10.4	15	14.9	30	12.2
80 – 84	14	9.7	6	5.9	20	8.2
85 +	9	6.3	7	6.9	16	6.5
Total	144	100.0	101	100.0	245	100.0

Majority of cases

FIGURE 15: DISTRIBUTION OF COLON AND RECTUM CANCER PATIENTS BY AGE GROUP






COLON AND RECTUM CANCER

Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	20	13.9	11	10.9	31	12.7
Stage II	35	24.3	23	22.8	58	23.7
Stage III	52	36.1	37	36.6	89	36.3
Stage IV	37	25.7	30	29.7	67	27.3
Total	144	100.0	101	100.0	245	100.0

FIGURE 16: DISTRIBUTION OF NEW COLON AND RECTUM CANCER PATIENTS BY STAGE ANDGENDER: 2025






COLON AND RECTUM CANCER

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology or Cytology	132	91.7	97	96.0	229	93.5
Endoscopy	12	8.3	4	4.0	16	6.5
Total	144	100.0	101	100.0	245	100.0

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	68	47.2	42	41.6	110	44.9
Regional lymph nodes	39	27.1	29	28.7	68	27.8
Distant metastasis	37	25.7	30	29.7	67	27.3
Total	144	100.0	101	100.0	245	100.0

FIGURE 17: DISTRIBUTION OF NEW COLON AND RECTUM CANCER PATIENTS BY EXTENSION AND GENDER: 2025





COLON AND RECTUM CANCER

TABLE 29

DISTRIBUTION OF NEW COLON AND RECTUM CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2025

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	46	31.9	37	36.6	83	33.9
Radiation	1	0.7	3	3.0	4	1.6
Chemotherapy	18	12.5	17	16.8	35	14.3
Immunotherapy	0	0.0	2	2.0	2	0.8
Surgery & Chemotherapy	36	25.0	20	19.8	56	22.9
Radiotherapy & Chemotherapy	4	2.8	2	2.0	6	2.4
Chemotherapy & Immunotherapy	3	2.1	1	1.0	4	1.6
Surgery, Radiotherapy & Chemotherapy	2	1.4	5	5.0	7	2.9
Surgery, Chemotherapy & Immunotherapy	1	0.7	0	0.0	1	0.4
Surgery, Chemotherapy & Targeted therapy	0	0.0	1	1.0	1	0.4
Surgery, Radiotherapy, Chemotherapy & Targeted therapy	0	0.0	1	1.0	1	0.4
Counseling	33	22.9	12	11.9	45	18.4
Total	144	100.0	101	100.0	245	100.0



COLON AND RECTUM CANCER

TABLE 30 DISTRIBUTION OF NEW COLON AND RECTUM CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2025						
Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	122	84.7	85	84.2	207	84.5
Deaths	22	15.3	16	15.8	38	15.5
Total	144	100.0	101	100.0	245	100.0

Survey: 1 May 2026





2

BREAST

CANCER



TABLE 31

TREND OF BREAST CANCER IN PHRAMONGKUTKLAO HOSPITAL : 2014 - 2025

Years	Number of patients		Total
	Male	Female	
2014	0	261	261
2015	2	197	199
2016	2	198	200
2017	5	166	171
2018	4	180	184
2019	3	206	209
2020	3	181	184
2021	2	210	212
2022	5	221	226
2023	2	187	189
2024	1	230	231
2025	1	186	187




BREAST CANCER

TABLE 32	DISTRIBUTION OF BREAST CANCER PATIENTS BY AGE GROUP AND GENDER : 2025					
Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 24	0	0.0	0	0.0	0	0.0
25 – 29	0	0.0	1	0.5	1	0.5
30 – 34	0	0.0	4	2.2	4	2.1
35 – 39	0	0.0	4	2.2	4	2.1
40 – 44	0	0.0	12	6.5	12	6.4
45 – 49	0	0.0	20	10.8	20	10.7
50 – 54	0	0.0	26	14.0	26	13.9
55 – 59	0	0.0	23	12.4	23	12.3
60 – 64	0	0.0	28	15.1	28	15.0
65 – 69	1	100.0	20	10.8	21	11.2
70 – 74	0	0.0	17	9.1	17	9.1
75 – 79	0	0.0	15	8.1	15	8.0
80 – 84	0	0.0	5	2.7	5	2.7
85 +	0	0.0	11	5.9	11	5.9
Total	1	100.0	186	100.0	187	100.0

Majority of cases

FIGURE 18: DISTRIBUTION OF BREAST CANCER PATIENTS BY AGE GROUP AND GENDER: 2025






BREAST CANCER

TABLE 33	DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY STAGE AND GENDER : 2025					
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	0	0.0	50	26.9	50	26.7
Stage II	0	0.0	71	38.2	71	38.0
Stage III	0	0.0	34	18.3	34	18.2
Stage IV	1	100.0	31	16.7	32	17.1
Total	1	100.0	186	100.0	187	100.0

FIGURE 19: DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY STAGE AND GENDER: 2025






BREAST CANCER

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	0	0.0	6	3.2	6	3.2
Histopathology or Cytology	1	100.0	180	96.8	181	96.8
Total	1	100.0	186	100.0	187	100.0

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	0	0.0	95	51.1	95	50.8
Regional lymph nodes	0	0.0	60	32.3	60	32.1
Distant metastasis	1	100.0	31	16.7	32	17.1
Total	1	100.0	186	100.0	187	100.0

FIGURE 20: DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY EXTENSION AND GENDER: 2025





BREAST CANCER

TABLE 36

DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2025

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	0	0.0	34	18.3	34	18.2
Radiation	0	0.0	6	3.2	6	3.2
Chemotherapy	1	100.0	24	12.9	25	13.4
Hormone	0	0.0	4	2.2	4	2.1
Targeted therapy	0	0.0	1	0.5	1	0.5
Surgery & Radiotherapy	0	0.0	6	3.2	6	3.2
Surgery & Chemotherapy	0	0.0	51	27.4	51	27.3
Surgery & Hormone	0	0.0	2	1.1	2	1.1
Surgery & Targeted therapy	0	0.0	2	1.1	2	1.1
Radiotherapy & Chemotherapy	0	0.0	4	2.2	4	2.1
Radiation & Targeted therapy	0	0.0	1	0.5	1	0.5
Chemotherapy & Immunotherapy	0	0.0	7	3.8	7	3.7
Chemotherapy & Targeted therapy	0	0.0	5	2.7	5	2.7
Hormone & Immunotherapy	0	0.0	1	0.5	1	0.5
Surgery, Radiotherapy & Chemotherapy	0	0.0	5	2.7	5	2.7
Surgery, Chemotherapy & Immunotherapy	0	0.0	3	1.6	3	1.6
Surgery, Chemotherapy & Targeted therapy	0	0.0	2	1.1	2	1.1



TABLE 36 DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2025						
Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiotherapy, Chemotherapy & Targeted therapy	0	0.0	1	0.5	1	0.5
Chemotherapy, Hormone & Immunotherapy	0	0.0	1	0.5	1	0.5
Surgery, Radiotherapy, Chemotherapy & Targeted therapy	0	0.0	1	0.5	1	0.5
Surgery, Chemotherapy, Hormone & Immunotherapy	0	0.0	1	0.5	1	0.5
Surgery, Chemotherapy, Immunotherapy & Targeted therapy	0	0.0	1	0.5	1	0.5
Radiotherapy, Chemotherapy, Immunotherapy & Targeted therapy	0	0.0	1	0.5	1	0.5
Radiotherapy, Hormone, Immunotherapy & Targeted therapy	0	0.0	1	0.5	1	0.5
Counseling	0	0.0	21	11.3	21	11.2
Total	1	100.0	186	100.0	187	100.0

TABLE 37 DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2025						
Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	0	0.0	173	93.0	173	92.5
Deaths	1	100.0	13	7.0	14	7.5
Total	1	100.0	186	100.0	187	100.0



3

BRONCHUS AND LUNG
CANCER



TABLE 38

TREND OF BRONCHUS AND LUNG CANCER IN PHRAMONGKUTKLAO
HOSPITAL : 2014 - 2025

Years	Number of patients		Total
	Male	Female	
2014	130	87	217
2015	120	81	201
2016	140	88	228
2017	102	67	169
2018	104	56	160
2019	132	91	223
2020	107	72	179
2021	117	82	199
2022	111	97	208
2023	108	88	196
2024	120	100	220
2025	96	82	178




BRONCHUS AND LUNG CANCER

TABLE 39	DISTRIBUTION OF BRONCHUS AND LUNG CANCER PATIENTS BY AGE GROUP AND GENDER : 2025					
Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 29	0	0.0	0	0.0	0	0.0
30 – 34	1	1.0	1	1.2	2	1.1
35 – 39	1	1.0	2	2.4	3	1.7
40 – 44	2	2.1	3	3.7	5	2.8
45 – 49	4	4.2	9	11.0	13	7.3
50 – 54	7	7.3	10	12.2	17	9.6
55 – 59	6	6.3	5	6.1	11	6.2
60 – 64	21	21.9	11	13.4	32	18.0
65 – 69	10	10.4	10	12.2	20	11.2
70 – 74	15	15.6	13	15.9	28	15.7
75 – 79	16	16.7	6	7.3	22	12.4
80 – 84	8	8.3	5	6.1	13	7.3
85 +	5	5.2	7	8.5	12	6.7
Total	96	100.0	82	100.0	178	100.0

Majority of cases

FIGURE 21: DISTRIBUTION OF BRONCHUS AND LUNG CANCER PATIENTS BY AGE GROUP ANDGENDER: 2025






BRONCHUS AND LUNG CANCER

TABLE 40	DISTRIBUTION OF NEW BRONCHUS AND LUNG CANCER PATIENTS BY STAGE AND GENDER : 2025					
	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	12	12.5	10	12.2	22	12.4
Stage II	12	12.5	12	14.6	24	13.5
Stage III	15	15.6	8	9.8	23	12.9
Stage IV	57	59.4	51	62.2	108	60.7
Unknown	0	0.0	1	1.2	1	0.6
Total	96	100.0	82	100.0	178	100.0

FIGURE 22: DISTRIBUTION OF NEW BRONCHUS AND LUNG CANCER PATIENTS BY STAGE ANDGENDER: 2025






BRONCHUS AND LUNG CANCER

Method of diagnosis	DISTRIBUTION OF NEW BRONCHUS AND LUNG CANCER PATIENTS BY METHOD OF DIAGNOSIS AND GENDER : 2025					
	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	2	2.1	1	1.2	3	1.7
Histopathology or Cytology	94	97.9	81	98.8	175	98.3
Total	96	100.0	82	100.0	178	100.0

Extension	DISTRIBUTION OF NEW BRONCHUS AND LUNG CANCER PATIENTS BY EXTENSION AND GENDER : 2025					
	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	29	30.2	25	30.5	54	30.3
Regional lymph nodes	11	11.5	8	9.8	19	10.7
Distant metastasis	56	58.3	49	59.8	105	59.0
Total	96	100.0	82	100.0	178	100.0

FIGURE 23: DISTRIBUTION OF NEW BRONCHUS AND LUNG CANCER PATIENTS BY EXTENSION AND GENDER: 2025





BRONCHUS AND LUNG CANCER

TABLE 43

DISTRIBUTION OF NEW BRONCHUS AND LUNG CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2025

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	27	28.1	17	20.7	44	24.7
Radiation	4	4.2	31	37.8	35	19.7
Chemotherapy	12	12.5	3	3.7	15	8.4
Hormone	0	0.0	10	12.2	10	5.6
Immunotherapy	3	3.1	1	1.2	4	2.2
Targeted therapy	2	2.1	0	0.0	2	1.1
Surgery & Radiotherapy	1	1.0	3	3.7	4	2.2
Surgery & Chemotherapy	7	7.3	0	0.0	7	3.9
Radiotherapy & Chemotherapy	2	2.1	5	6.1	7	3.9
Radiation & Targeted therapy	1	1.0	2	2.4	3	1.7
Chemotherapy & Immunotherapy	8	8.3	0	0.0	8	4.5
Chemotherapy & Targeted therapy	1	1.0	4	4.9	5	2.8
Surgery, Radiotherapy & Targeted therapy	1	1.0	2	2.4	3	1.7
Surgery, Chemotherapy & Immunotherapy	1	1.0	0	0.0	1	0.6
Surgery, Chemotherapy & Targeted therapy	0	0.0	1	1.2	1	0.6
Radiotherapy, Chemotherapy & Immunotherapy	0	0.0	1	1.2	1	0.6
Radiotherapy, Chemotherapy & Targeted therapy	1	1.0	1	1.2	2	1.1
Chemotherapy, Immunotherapy & Targeted therapy	4	4.2	0	0.0	4	2.2
Counseling	21	21.9	1	1.2	22	12.4
Total	96	100.0	82	100.0	178	100.0

TABLE 44

DISTRIBUTION OF NEW BRONCHUS AND LUNG CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2025

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	67	69.8	61	74.4	128	71.9
Deaths	29	30.2	21	25.6	50	28.1
Total	96	100.0	82	100.0	178	100.0

Survey: 1 May 2026



4

PROSTATE GLAND
CANCER





TABLE 45	DISTRIBUTION OF PROSTATE GLAND CANCER PATIENTS BY AGE GROUP AND GENDER : 2025			
	Male		Total	
	Number	Percent	Number	Percent
00 – 49	0	0.0	0	0.0
50 – 54	3	2.6	3	2.6
55 – 59	2	1.7	2	1.7
60 – 64	19	16.2	19	16.2
65 – 69	26	22.2	26	22.2
70 – 74	27	23.1	27	23.1
75 – 79	27	23.1	27	23.1
80 – 84	10	8.5	10	8.5
85 +	3	2.6	3	2.6
Total	117	100.0	117	100.0

 Majority of cases

FIGURE 24: DISTRIBUTION OF PROSTATE GLAND CANCER PATIENTS BY AGE GROUP ANDGENDER: 2025






PROSTATE GLAND CANCER

TABLE 46	DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY STAGE AND GENDER : 2025			
Staging	Male		Total	
	Number	Percent	Number	Percent
Stage I	38	32.5	38	32.5
Stage II	34	29.1	34	29.1
Stage III	20	17.1	20	17.1
Stage IV	25	21.4	25	21.4
Total	117	100.0	117	100.0

FIGURE 25: DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY STAGE ANDGENDER: 2025






PROSTATE GLAND CANCER

TABLE 47	DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY METHOD OF DIAGNOSIS AND GENDER : 2025			
	Method of diagnosis	Male		Total
		Number	Percent	Number Percent
	Radiology	1	0.9	1 0.9
	Histopathology or Cytology	116	99.1	116 99.1
	Total	117	100.0	117 100.0

TABLE 48	DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY EXTENSION AND GENDER : 2025			
	Extension	Male		Total
		Number	Percent	Number Percent
	Localized	91	77.8	91 77.8
	Regional lymph nodes	4	3.4	4 3.4
	Distant metastasis	22	18.8	22 18.8
	Total	117	100.0	117 100.0

FIGURE 26: DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY EXTENSION AND GENDER: 2025





PROSTATE GLAND CANCER


Treatment modality	Male		Total	
	Number	Percent	Number	Percent
Surgery	29	16.5	29	16.5
Radiation	13	7.4	13	7.4
Chemotherapy	6	3.4	6	3.4
Targeted therapy	2	1.1	2	1.1
Surgery & Radiotherapy	2	1.1	2	1.1
Surgery & Chemotherapy	4	2.3	4	2.3
Radiotherapy & Chemotherapy	1	0.6	1	0.6
Chemotherapy & Immunotherapy	1	0.6	1	0.6
Surgery, Chemotherapy & Targeted therapy	1	0.6	1	0.6
Counseling	117	66.5	117	66.5
Total	176	100.0	176	100.0

Follow up status	Male		Total	
	Number	Percent	Number	Percent
Alive	108	92.3	108	92.3
Deaths	9	7.7	9	7.7
Total	117	100.0	117	100.0

Survey: 1 May 2026

5


THYROID CANCER



Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 - 14	0	0.0	0	0.0	0	0.0
15 - 19	1	4.5	0	0.0	1	0.9
20 - 24	1	4.5	1	1.2	2	1.9
25 - 29	2	9.1	3	3.6	5	4.7
30 - 34	0	0.0	14	16.7	14	13.2
35 - 39	0	0.0	12	14.3	12	11.3
40 - 44	3	13.6	9	10.7	12	11.3
45 - 49	3	13.6	14	16.7	17	16.0
50 - 54	1	4.5	7	8.3	8	7.5
55 - 59	1	4.5	9	10.7	10	9.4
60 - 64	3	13.6	5	6.0	8	7.5
65 - 69	1	4.5	4	4.8	5	4.7
70 - 74	1	4.5	3	3.6	4	3.8
75 - 79	1	4.5	2	2.4	3	2.8
80 - 84	3	13.6	1	1.2	4	3.8
85 +	1	4.5	0	0.0	1	0.9
Total	22	100.0	84	100.0	106	100.0

Majority of cases

FIGURE 27: DISTRIBUTION OF THYROID CANCER PATIENTS BY AGE GROUP AND GENDER: 2025






THYROID CANCER

TABLE 52	DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY STAGE AND GENDER : 2025					
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	8	36.4	44	52.4	52	49.1
Stage II	7	31.8	17	20.2	24	22.6
Stage III	5	22.7	11	13.1	16	15.1
Stage IV	2	9.1	12	14.3	14	13.2
Total	22	100.0	84	100.0	106	100.0

FIGURE 28: DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY STAGE AND GENDER: 2025






THYROID CANCER

TABLE 53	DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY METHOD OF DIAGNOSIS AND GENDER : 2025					
	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	0	0.0	2	2.4	2	1.9
Histopathology or Cytology	22	100.0	82	97.6	104	98.1
Total	22	100.0	84	100.0	106	100.0

TABLE 54	DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY EXTENSION AND GENDER : 2025					
	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	17	77.3	60	71.4	77	72.6
Regional lymph nodes	3	13.6	13	15.5	16	15.1
Distant metastasis	2	9.1	11	13.1	13	12.3
Total	22	100.0	84	100.0	106	100.0

FIGURE 29: DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY EXTENSION AND GENDER: 2025





THYROID CANCER

TABLE 55

DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2025


Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	8	36.4	25	29.8	33	31.1
Radiation	7	31.8	27	32.1	34	32.1
Surgery & Radiotherapy	5	22.7	20	23.8	25	23.6
Surgery & Chemotherapy	0	0.0	2	2.4	2	1.9
Counseling	2	9.1	10	11.9	12	11.3
Total	22	100.0	84	100.0	106	100.0

TABLE 56

DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2025

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	22	100.0	84	100.0	106	100.0
Deaths	0	0.0	0	0.0	0	0.0
Total	22	100.0	84	100.0	106	100.0

Survey: 1 May 2026






6

LIVER & INTRAHEPATIC BILE DUCTS
CANCER

TABLE 57	DISTRIBUTION OF LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY AGE GROUP AND GENDER : 2025					
	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 24	0	0.0	0	0.0	0	0.0
25 – 29	1	1	0	0	1	1.1
30 – 34	0	0	0	0	0	0.0
35 – 39	0	0	0	0	0	0.0
40 – 44	1	1	0	0	1	1.1
45 – 49	5	7.5	0	0.0	5	5.4
50 – 54	14	20.9	1	3.8	15	16.1
55 – 59	9	13.4	3	11.5	12	12.9
60 – 64	9	13.4	3	11.5	12	12.9
65 – 69	9	13.4	2	7.7	11	11.8
70 – 74	10	14.9	5	19.2	15	16.1
75 – 79	3	4.5	6	23.1	9	9.7
80 – 84	2	3.0	4	15.4	6	6.5
85+	4	6.0	2	7.7	6	6.5
Total	67	100.0	26	100.0	93	100.0

Majority of cases

FIGURE 30: DISTRIBUTION OF LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY AGE GROUP ANDGENDER: 2025






LIVER & INTRAHEPATIC BILE DUCTS CANCER

TABLE 58	DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY STAGE AND GENDER : 2025					
	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	12	17.9	5	19.2	17	18.3
Stage II	15	22.4	9	34.6	24	25.8
Stage III	14	20.9	5	19.2	19	20.4
Stage IV	26	38.8	7	26.9	33	35.5
Total	67	100.0	26	100.0	93	100.0

FIGURE 31: DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY STAGE ANDGENDER:2025






LIVER & INTRAHEPATIC BILE DUCTS CANCER

TABLE 59	DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY METHOD AND GENDER : 2025					
	Method of diagnosis	Male		Female		Total
		Number	Percent	Number	Percent	Number Percent
	Histopathology or Cytology	38	56.7	17	65.4	55 59.1
	Tumor marker	29	43.3	9	34.6	38 40.9
	Total	67	100.0	26	100.0	93 100.0

TABLE 60	DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY EXTENSION AND GENDER : 2025					
	Extension	Male		Female		Total
		Number	Percent	Number	Percent	Number Percent
	Localized	48	71.6	19	73.1	67 72.0
	Regional lymph nodes	2	3.0	1	3.8	3 3.2
	Distant metastasis	17	25.4	6	23.1	23 24.7
	Total	67	100.0	26	100.0	93 100.0

FIGURE 32: DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY EXTENSION AND GENDER: 2025





LIVER & INTRAHEPATIC BILE DUCTS CANCER

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	8	11.9	7	26.9	15	16.1
Radiation	1	1.5	0	0.0	1	1.1
Chemotherapy	9	13.4	3	11.5	12	12.9
Interventional	16	23.9	3	11.5	19	20.4
Surgery & Chemotherapy	1	1.5	3	11.5	4	4.3
Surgery & Interventional	2	3.0	1	3.8	3	3.2
Radiotherapy & Chemotherapy	0	0.0	1	3.8	1	1.1
Chemotherapy & Immunotherapy	1	1.5	0	0.0	1	1.1
Chemotherapy & Interventional	14	20.9	4	15.4	18	19.4
Surgery, Radiotherapy & Chemotherapy	1	1.5	0	0.0	1	1.1
Surgery, Chemotherapy & Immunotherapy	1	1.5	0	0.0	1	1.1
Surgery, Chemotherapy & Interventional	3	4.5	1	3.8	4	4.3
Chemotherapy, Immunotherapy & Interventional	0	0.0	1	3.8	1	1.1
Counseling	10	14.9	2	7.7	12	12.9
Total	67	100.0	26	100.0	93	100.0

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	56	83.6	25	96.2	81	87.1
Deaths	11	16.4	1	3.8	12	12.9
Total	67	100.0	26	100.0	93	100.0

Survey: 1 May 2026



● MALE ●

TABLE 63	DISTRIBUTION OF NEW CANCER IN MALE BY AGE - GROUP : 2025																			
ICD_10	Site	Age	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80	85
			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Total	4	9	14	19	24	29	34	39	44	49	54	59	64	69	74	79	84	
C00 - C14	Malignant neoplasm of lip, oral cavity & pharynx	33	0	0	0	1	0	2	0	1	1	4	9	6	2	2	1	3	1	0
C13	Hypopharynx	11	0	0	0	0	0	0	0	0	2	1	1	0	4	1	1	1	0	0
C15 - C17, C21, C23 - C26	Digestive organ	56	0	0	0	0	2	1	0	2	3	2	4	12	7	6	6	5	0	6
C18 - C20	Colon & Rectum	144	0	0	0	0	1	1	0	4	4	6	9	19	18	27	17	15	14	9
C22	Liver & intrahepatic bile ducts	67	0	0	0	0	0	1	0	0	1	5	14	9	9	9	10	3	2	4
C25	Pancreas	20	0	0	0	0	0	0	0	0	0	6	1	3	1	3	1	1	2	2
C30 - C39	Malignant neoplasm of respiratory & Intrathoracic organs	21	0	0	0	0	0	0	1	0	1	3	4	5	3	0	0	1	1	2
C34	Bronchus & Lung	96	0	0	0	0	0	0	1	1	2	4	7	6	21	10	15	16	8	5
C40, C41	Bone & articular cartilage	7	0	0	0	0	0	1	0	1	0	1	0	0	1	1	1	0	1	0
C43, C44	Skin	31	0	0	0	0	0	1	0	0	0	0	2	2	3	1	5	5	5	7
C45 - C49	Malignant neoplasm of mesothelial & soft tissue	19	0	0	0	0	1	1	1	2	0	0	2	3	1	3	1	1	2	1
C50	Breast	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
C60	Malignant neoplasm of penis	2	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0
C61	Prostate gland	117	0	0	0	0	0	0	0	0	0	0	3	2	19	26	27	27	10	3
C62, C63	Malignant neoplasm of testis	7	0	0	0	0	3	0	2	2	0	0	0	0	0	0	0	0	0	0
C64 - C66	Kidney, renal pelvis & ureter	27	1	0	0	0	0	0	1	0	2	2	2	2	5	4	3	4	0	1
C67	Bladder	26	0	0	0	0	0	0	0	0	0	1	0	3	2	5	2	6	6	1
C69, C70	Eye & Meninges	3	0	0	0	0	0	0	0	1	0	0	0	1	0	0	1	0	0	0
C71, C72	Brain	14	0	0	0	1	1	1	1	1	2	0	2	0	1	1	2	0	1	0
C73	Thyroid	22	0	0	0	1	1	2	0	0	3	3	1	1	3	1	1	1	3	1
C74, C75	Malignant neoplasm of other endocrine glands and relate structures	6	0	0	0	1	2	0	0	0	0	1	1	0	1	0	0	0	0	0
C76 - C80	Malignant neoplasm of ill-defined, secondary & unspecified sites	2	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0
C81	Hodgkin's disease	8	0	0	0	1	0	4	1	0	0	0	1	0	0	1	0	0	0	0
C82 - C88	Non-Hodgkin's lymphoma	43	0	0	0	0	0	0	3	3	3	4	7	6	3	5	3	4	0	2
C90	Multiple myeloma & malignant plasma cell neoplasms	20	0	0	0	0	0	0	1	0	1	1	2	2	5	3	0	2	1	2
C91 - C95	Leukemia	35	4	0	1	1	3	3	1	2	1	3	2	1	4	1	4	4	0	0
Total		838	5	0	1	6	14	18	13	20	26	47	75	85	114	111	101	99	57	46



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

● FEMALE ●

TABLE 64		DISTRIBUTION OF NEW CANCER IN FEMALE BY AGE - GROUP : 2025																			
ICD_10	Site	Age	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80	85	
			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
		Total	4	9	14	19	24	29	34	39	44	49	54	59	64	69	74	79	84		
C00 - C14	Malignant neoplasm of lip, oral cavity & pharynx	20	0	0	0	0	0	0	0	2	2	1	2	3	3	1	2	3	1	0	
C15 - C17, C21 - C24, C26	Digestive organ	30	0	1	0	0	0	2	0	1	1	2	3	4	4	4	3	3	1	1	
C18 - C20	Colon & Rectum	101	0	0	0	0	0	0	1	1	7	7	7	9	15	10	16	15	6	7	
C22	Liver & intrahepatic bile ducts	26	0	0	0	0	0	0	0	0	0	0	1	3	3	2	5	6	4	2	
C25	Pancreas	19	0	0	0	0	0	1	0	1	0	0	0	0	2	8	2	0	3	2	
C30 - C39	Malignant neoplasm of respiratory & Intrathoracic organs	6	0	0	0	0	0	0	0	0	0	0	1	1	0	1	1	1	0	1	
C34	Bronchus & Lung	82	0	0	0	0	0	0	1	2	3	9	10	5	11	10	13	6	5	7	
C40, C41	Bone & articular cartilage	11	0	0	1	0	0	0	0	1	0	1	1	0	2	3	0	2	0	0	
C43, C44	Skin	19	0	0	0	0	0	0	0	0	0	2	0	1	0	4	2	1	2	7	
C45 - C49	Malignant neoplasm of mesothelial & soft tissue	8	0	0	0	0	0	0	1	0	1	0	2	1	1	1	1	0	0	0	
C50	Breast	186	0	0	0	0	0	1	4	4	12	20	26	23	28	20	17	15	5	11	
C51, C52	Malignant neoplasm of placenta	2	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	
C53	Cervix	62	0	0	0	0	0	3	3	10	11	11	9	3	3	5	2	1	1	0	
C54, C55	Endometrium	68	0	0	0	0	0	0	2	1	5	7	5	11	9	9	9	5	1	4	
C56	Ovary	55	0	0	1	0	0	3	1	2	5	6	9	6	9	4	4	1	3	1	
C62, C63	Malignant neoplasm of testis	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	
C64, C65, C66	Kidney, renal pelvis & ureter	14	0	0	0	0	0	0	1	1	1	0	3	2	4	1	1	0	0	0	
C67	Bladder	14	0	0	0	0	0	0	0	0	1	0	1	0	1	0	2	3	4	2	
C69, C70	Eye & Meninges	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	
C71, C72	Brain	4	0	0	0	0	0	0	0	0	0	0	2	0	1	1	0	0	0	0	
C73	Thyroid gland	84	0	0	0	0	1	3	14	12	9	14	7	9	5	4	3	2	1	0	
C74, C75	Malignant neoplasm of other endocrine glands and relate structures	3	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	0	
C81	Hodgkin's disease	3	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	1	0	0	
C82- C88	Non-Hodgkin's lymphoma	37	0	1	0	1	1	0	0	2	1	4	1	4	9	1	3	2	6	1	
C90	Multiple myeloma & malignant plasma cell neoplasms	15	0	0	0	0	0	0	0	0	0	0	3	2	8	1	1	0	0	0	
C91 - C95	Leukemia	26	1	0	1	0	1	1	1	0	2	5	2	0	5	0	4	3	0	0	
Total		898	1	2	3	1	6	14	29	40	62	89	97	87	124	90	92	71	44	46	



TABLE 65		DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2025			
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C00-C14	Malignant neoplasm of lip, oral cavity & pharynx		33	20	53
C009	8070/6	Squamous cell carcinoma, metastatic, NOS	0	1	1
C01	8070/3	Squamous cell carcinoma, NOS	3	0	3
C020	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8071/3	Squamous cell carcinoma, keratinizing, NOS	2	0	2
C021	8070/3	Squamous cell carcinoma, NOS	2	1	3
	8073/6	Squamous cell carcinoma, spindle cell, metastatic	1	0	1
C023	8071/3	Squamous cell carcinoma, keratinizing, NOS	1	0	1
C029	8070/3	Squamous cell carcinoma, NOS	2	3	5
C049	8070/3	Squamous cell carcinoma, NOS	1	0	1
C051	8070/3	Squamous cell carcinoma, NOS	2	0	2
C062	8070/3	Squamous cell carcinoma, NOS	0	1	1
C07	8140/3	Adenocarcinoma, NOS	1	0	1
	8550/6	Acinar cell carcinoma, metastatic	0	1	1
C080	8010/3	Carcinoma, NOS	0	1	1
C088	8010/3	Carcinoma, NOS	0	1	1
C089	8010/3	Carcinoma, NOS	0	3	3
	8140/3	Adenocarcinoma, NOS	0	1	1
C090	8070/6	Squamous cell carcinoma, metastatic, NOS	0	1	1
C099	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	2	0	2
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C100	8070/3	Squamous cell carcinoma, NOS	1	0	1
C109	8070/3	Squamous cell carcinoma, NOS	4	0	4
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	1	2
C110	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8073/3	Squamous cell carcinoma, spindle cell	0	1	1
C119	8010/3	Carcinoma, NOS	2	0	2
	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8073/3	Squamous cell carcinoma, spindle cell	1	2	3
C140	8070/3	Squamous cell carcinoma, NOS	3	0	3
	8071/3	Squamous cell carcinoma, keratinizing, NOS	1	0	1
C00-C14	Malignant neoplasm of lip, oral cavity & pharynx		11	0	11
C131	8000/3	Neoplasm, malignant	1	0	1
	8070/3	Squamous cell carcinoma, NOS	2	0	2
C139	8000/3	Neoplasm, malignant	1	0	1
	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	3	0	3
	8070/6	Squamous cell carcinoma, metastatic, NOS	3	0	3



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

TABLE 65		DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2025			
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C15-C17, C21-C24	Digestive organ		56	30	86
C150	8070/3	Squamous cell carcinoma, NOS	2	0	2
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C151	8070/3	Squamous cell carcinoma, NOS	5	0	5
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C154	8070/3	Squamous cell carcinoma, NOS	3	0	3
C159	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	2	0	2
	8070/6	Squamous cell carcinoma, metastatic, NOS	3	0	3
C160	8000/3	Neoplasm, malignant	0	1	1
	8140/3	Adenocarcinoma, NOS	1	0	1
C161	8000/3	Neoplasm, malignant	1	1	2
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
C162	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	0	2	2
	8140/6	Adenocarcinoma, metastatic, NOS	3	1	4
C163	8140/3	Adenocarcinoma, NOS	3	0	3
	8140/6	Adenocarcinoma, metastatic, NOS	2	0	2
C169	8010/3	Carcinoma, NOS	2	2	4
	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	1	0	1
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8246/6	Neuroendocrine carcinoma, metastatic, NOS	0	1	1
	8336/6	Hyalinizing trabecular adenoma, metastatic	1	0	1
	8936/3	Gastrointestinal stromal sarcoma	1	0	1
	8936/6	Gastrointestinal stromal sarcoma, metastatic	0	1	1
C170	8140/3	Adenocarcinoma, NOS	2	1	3
	8140/6	Adenocarcinoma, metastatic, NOS	1	1	2
	8336/3	Hyalinizing trabecular adenoma	1	0	1
C171	8046/6	Non-small cell carcinoma, metastatic	1	0	1
C172	8140/3	Adenocarcinoma, NOS	0	1	1
	8936/3	Gastrointestinal stromal sarcoma	1	0	1
C179	8936/3	Gastrointestinal stromal sarcoma	0	1	1
C210	8140/3	Adenocarcinoma, NOS	0	1	1
C211	8000/3	Neoplasm, malignant	1	0	1
	8073/3	Squamous cell carcinoma, spindle cell	1	0	1
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
C218	8000/3	Neoplasm, malignant	3	1	4
	8140/3	Adenocarcinoma, NOS	2	2	4
	8140/6	Adenocarcinoma, metastatic, NOS	1	1	2



TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2025					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C23	8000/3	Neoplasm, malignant	0	1	1
	8000/3	Neoplasm, malignant	0	1	1
	8140/6	Adenocarcinoma, metastatic, NOS	0	3	3
C240	8140/3	Adenocarcinoma, NOS	1	1	2
	8140/6	Adenocarcinoma, metastatic, NOS	1	1	2
C241	8010/3	Carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	3	0	3
C261	9120/3	Hemangiosarcoma	1	0	1
C269	8140/6	Adenocarcinoma, metastatic, NOS	1	1	2
C18-C20	Colon & Rectum		144	101	245
C180	8140/3	Adenocarcinoma, NOS	4	3	7
	8140/6	Adenocarcinoma, metastatic, NOS	2	2	4
	8246/3	Neuroendocrine carcinoma, NOS	1	0	1
C181	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8480/6	Pseudomyxoma peritonei	0	1	1
C182	8140/3	Adenocarcinoma, NOS	7	4	11
	8140/6	Adenocarcinoma, metastatic, NOS	3	1	4
C183	8000/3	Neoplasm, malignant	1	0	1
	8140/3	Adenocarcinoma, NOS	1	3	4
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
C184	8000/3	Neoplasm, malignant	1	0	1
	8010/3	Carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	2	2	4
	8140/6	Adenocarcinoma, metastatic, NOS	3	0	3
C185	8140/3	Adenocarcinoma, NOS	3	1	4
C186	8010/3	Carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	4	5	9
	8140/6	Adenocarcinoma, metastatic, NOS	1	2	3
C187	8000/3	Neoplasm, malignant	2	1	3
	8000/3	Neoplasm, malignant	2	3	5
	8140/3	Adenocarcinoma, NOS	35	26	61
	8140/6	Adenocarcinoma, metastatic, NOS	13	9	22
	8480/3	Mucinous adenocarcinoma	1	0	1
	8480/6	Pseudomyxoma peritonei	1	0	1
C188	8000/3	Neoplasm, malignant	1	0	1
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
C189	8010/3	Carcinoma, NOS	0	1	1
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	6	1	7
	8140/6	Adenocarcinoma, metastatic, NOS	6	5	11



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

TABLE 65	DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2025				
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C19	8000/3	Neoplasm, malignant	0	1	1
	8140/3	Adenocarcinoma, NOS	5	3	8
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
C20	8000/3	Neoplasm, malignant	5	0	5
	8140/3	Adenocarcinoma, NOS	26	18	44
	8140/6	Adenocarcinoma, metastatic, NOS	4	4	8
	8246/3	Neuroendocrine carcinoma, NOS	1	1	2
C22	Liver & intrahepatic bile ducts		67	26	93
C220	8000/3	Neoplasm, malignant	20	7	27
	8000/3	Neoplasm, malignant	6	1	7
	8010/3	Carcinoma, NOS	2	0	2
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8160/3	Cholangiocarcinoma, metastatic	0	1	1
	8160/6	Cholangiocarcinoma, metastatic	1	0	1
	8170/3	Cholangiocarcinoma, metastatic	16	4	20
	8170/6	Cholangiocarcinoma, metastatic	4	1	5
	8174/3	Cholangiocarcinoma, metastatic	1	0	1
	8180/3	Cholangiocarcinoma, metastatic	2	1	3
C221	8000/3	Cholangiocarcinoma, metastatic	2	0	2
	8010/3	Cholangiocarcinoma, metastatic	1	0	1
	8010/6	Cholangiocarcinoma, metastatic	2	0	2
	8140/3	Cholangiocarcinoma, metastatic	1	4	5
	8140/6	Cholangiocarcinoma, metastatic	6	3	9
	8160/3	Cholangiocarcinoma, metastatic	1	2	3
C229	8000/3	Neoplasm, malignant	1	0	1
	8180/3	Combined hepatocellular carcinoma	1	0	1
C25	Pancreas				
C250	8010/3	Carcinoma, NOS	1	0	1
	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	3	2	5
	8140/6	Adenocarcinoma, metastatic, NOS	2	4	6
C251	8010/3	Carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	2	1	3
	8140/6	Adenocarcinoma, metastatic, NOS	3	5	8



TABLE 65	DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2025				
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C252	8140/3	Adenocarcinoma, NOS	1	0	1
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8806/3	Desmoplastic small round cell tumor	0	1	1
C253	8000/3	Neoplasm, malignant	0	2	2
	8140/6	Adenocarcinoma, metastatic, NOS	2	0	2
	8246/3	Neuroendocrine carcinoma, NOS	1	0	1
C254	9364/6	Peripheral neuroectodermal tumor	1	0	1
C259	8000/3	Neoplasm, malignant	0	2	2
	8140/6	Adenocarcinoma, metastatic, NOS	2	1	3
C30-C33, C35-C39	Malignant neoplasm of respiratory & Intrathoracic organs		21	6	27
C300	8070/3	Squamous cell carcinoma, NOS	3	0	3
	8090/3	Basal cell carcinoma, NOS	0	1	1
	9220/3	Juxtacortical chondrosarcoma	0	1	1
C301	8010/3	Carcinoma, NOS	1	0	1
C320	8070/3	Squamous cell carcinoma, NOS	5	1	6
C321	8070/3	Squamous cell carcinoma, NOS	4	0	4
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
	8073/3	Squamous cell carcinoma, spindle cell	1	0	1
C322	8070/3	Squamous cell carcinoma, NOS	1	0	1
C329	8070/3	Squamous cell carcinoma, NOS	2	0	2
C37	8581/3	Thymoma, type A, malignant	1	1	2
	8584/3	Thymoma, typeB2, malignant	1	0	1
	8585/3	Thymoma, typeB3, malignant	0	1	1
C381	8583/3	Thymoma, type B, malignant	0	1	1
	8803/6	Small cell sarcoma, metastatic	1	0	1
C34	Bronchus & lung		96	82	178
C340	8000/3	Neoplasm, malignant	0	1	1
	8041/6	Small cell carcinoma, metastatic, NOS	1	0	1
	8046/3	Small cell carcinoma, NOS	2	3	5
	8046/6	Small cell carcinoma, NOS	3	1	4
	8070/3	Small cell carcinoma, NOS	1	0	1
	8070/6	Small cell carcinoma, NOS	1	0	1
	8140/3	Small cell carcinoma, NOS	5	3	8
	8140/6	Small cell carcinoma, NOS	4	2	6
	8480/3	Small cell carcinoma, NOS	1	0	1
	8583/6	Small cell carcinoma, NOS	0	1	1
C341	8046/3	Small cell carcinoma, NOS	2	0	2
	8070/6	Small cell carcinoma, NOS	1	0	1
	8140/3	Small cell carcinoma, NOS	2	4	6
	8140/6	Small cell carcinoma, NOS	6	2	8



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2025					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C342	8140/3	Small cell carcinoma, NOS	3	0	3
	8480/3	Small cell carcinoma, NOS	1	0	1
C343	8000/3	Small cell carcinoma, NOS	1	0	1
	8010/3	Small cell carcinoma, NOS	1	1	2
	8010/6	Small cell carcinoma, NOS	1	1	2
	8041/3	Small cell carcinoma, NOS	1	0	1
	8046/3	Small cell carcinoma, NOS	0	1	1
	8046/6	Small cell carcinoma, NOS	0	1	1
	8140/3	Small cell carcinoma, NOS	2	2	4
	8140/6	Small cell carcinoma, NOS	4	5	9
	8480/3	Small cell carcinoma, NOS	1	0	1
C349	8000/3	Small cell carcinoma, NOS	2	2	4
	8000/3	Small cell carcinoma, NOS	0	2	2
	8010/3	Small cell carcinoma, NOS	0	1	1
	8010/6	Small cell carcinoma, NOS	3	3	6
	8041/3	Small cell carcinoma, NOS	1	0	1
	8041/6	Small cell carcinoma, metastatic, NOS	1	2	3
	8046/3	Non-small cell carcinoma	2	1	3
	8046/6	Non-small cell carcinoma, metastatic	6	2	8
	8070/3	Squamous cell carcinoma, NOS	2	0	2
	8073/3	Squamous cell carcinoma, spindle cell	1	0	1
	8140/3	Adenocarcinoma, NOS	10	11	21
	8140/6	Adenocarcinoma, metastatic, NOS	24	28	52
	8246/3	Neuroendocrine carcinoma, NOS	0	1	1
	8480/3	Mucinous adenocarcinoma	0	1	1
C40, C41	Bone & articular cartilage		7	11	18
C401	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
	8801/6	Spindle cell sarcoma, metastatic	1	0	1
C402	9591/6	Malignant lymphoma, non-Hodgkin, NOS	1	0	1
	8010/3	Carcinoma, NOS	1	0	1
	8800/3	Sarcoma, NOS	1	0	1
	8890/3	Leiomyosarcoma, NOS	0	1	1
	9180/3	Osteosarcoma, NOS	0	4	4
	9220/3	Chondrosarcoma, NOS	0	1	1
	9221/3	Juxtacortical chondrosarcoma	0	1	1
C411	8000/3	Neoplasm, malignant	0	1	1



TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2025					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C414	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	9220/3	Chondrosarcoma, NOS	0	1	1
	9370/3	Chordoma, NOS	1	0	1
C419	9220/3	Chondrosarcoma, NOS	0	1	1
	9250/3	Craniopharyngioma	1	0	1
C43-C44	Skin		31	19	50
C431	8090/3	Basal cell carcinoma, NOS	0	1	1
	8480/3	Mucinous adenocarcinoma	1	0	1
	8721/3	Nodular melanoma	1	0	1
C432	8070/3	Squamous cell carcinoma, NOS	0	1	1
C433	8720/3	Malignant melanoma, NOS	1	0	1
C434	8010/3	Carcinoma, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	1	0	1
C435	8147/3	Basal cell Adenocarcinoma	1	0	1
	8720/3	Malignant melanoma, NOS	2	0	2
C437	8720/3	Malignant melanoma, NOS	1	0	1
C439	8090/3	Basal cell carcinoma, NOS	1	0	1
	8720/6	Malignant melanoma, metastatic, NOS	0	1	1
C440	8090/3	Basal cell carcinoma, NOS	1	0	1
C441	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8090/3	Basal cell carcinoma, NOS	1	1	2
C442	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8832/3	Dermatofibrosarcoma, NOS	0	1	1
C443	8070/3	Squamous cell carcinoma, NOS	2	2	4
	8090/3	Basal cell carcinoma, NOS	4	3	7
C444	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8090/3	Basal cell carcinoma, NOS	3	0	3
C445	8070/3	Squamous cell carcinoma, NOS	2	1	3
C446	8090/3	Basal cell carcinoma, NOS	1	0	1
C447	8070/3	Squamous cell carcinoma, NOS	1	1	2
C448	8070/3	Squamous cell carcinoma, NOS	1	0	1
C449	8000/3	Neoplasm, malignant	0	1	1
	8070/3	Squamous cell carcinoma, NOS	2	0	2
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
	8090/3	Basal cell carcinoma, NOS	1	4	5



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2025					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C46-C49	Malignant neoplasm of mesothelial & soft tissue		19	8	27
C469	8801/6	Spindle cell sarcoma, metastatic	1	0	1
C479	8890/6	Leiomyosarcoma, metastatic, NOS	1	0	1
	9540/3	Malignant peripheral nerve sheath tumor	0	1	1
C480	8801/3	Spindle cell sarcoma	1	1	2
	8801/6	Spindle cell sarcoma, metastatic	1	0	1
C490	8803/3	Small cell sarcoma	1	0	1
	9040/3	Synovial sarcoma, NOS	1	0	1
C491	8800/3	Sarcoma, NOS	1	1	2
	8801/3	Spindle cell sarcoma	1	0	1
	8801/6	Spindle cell sarcoma, metastatic	1	0	1
C492	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8720/6	Malignant melanoma, metastatic, NOS	1	0	1
	8802/3	Giant cell sarcoma	1	0	1
	8802/6	Giant cell sarcoma, metastatic	1	0	1
	8805/3	Undifferentiated sarcoma	1	0	1
	8852/6	Myxoid liposarcoma, metastatic	0	1	1
	8858/3	Round cell liposarcoma	0	1	1
	9041/3	Synovial sarcoma, spindle cell	0	1	1
C494	8804/3	Epithelioid sarcoma	1	0	1
C495	8850/3	Liposarcoma, NOS	0	1	1
	8852/3	Myxoid liposarcoma	0	1	1
C496	8832/3	Dermatofibrosarcoma, NOS	1	0	1
C499	8800/3	Sarcoma, NOS	1	0	1
	8850/3	Liposarcoma, NOS	1	0	1
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	1	0	1
C50	Breast		1	186	187
C500	8010/3	Carcinoma, NOS	0	1	1
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	0	3	3
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	3	3
C501	8500/3	Infiltrating duct carcinoma, NOS	0	6	6
C502	8500/3	Infiltrating duct carcinoma, NOS	0	4	4
C503	8010/6	Carcinoma, metastatic, NOS	0	1	1
C504	8000/3	Neoplasm, malignant	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	0	7	7
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	2	2



TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2025					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C505	8500/3	Infiltrating duct carcinoma, NOS	0	2	2
C506	8500/3	Infiltrating duct carcinoma, NOS	0	1	1
C509	8000/3	Neoplasm, malignant	0	5	5
	8000/3	Neoplasm, malignant	0	1	1
	8010/3	Carcinoma, NOS	0	2	2
	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	1	1
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8480/3	Mucinous adenocarcinoma	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	0	119	119
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	1	22	23
	9250/3	Giant cell tumor of bone, malignant	0	1	1
C51-C52, C57-C58	Malignant neoplasms of female genital organs		0	2	2
C519	8720/3	Malignant melanoma, NOS	0	2	2
C53	Cervix				
C530	8010/3	Carcinoma, NOS	0	3	3
	8070/6	Squamous cell carcinoma, metastatic, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	10	10
C531	8010/3	Carcinoma, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	0	22	22
	8070/6	Squamous cell carcinoma, metastatic, NOS	0	2	2
	8073/3	Squamous cell carcinoma, spindle cell	0	3	3
	8073/6	Squamous cell carcinoma, spindle cell, metastatic	0	1	1
	8140/3	Adenocarcinoma, NOS	0	1	1
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8380/3	Endometrioid adenocarcinoma, NOS	0	1	1
C539	8000/3	Neoplasm, malignant	0	1	1
	8010/3	Carcinoma, NOS	0	1	1
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	0	11	11
	8140/3	Adenocarcinoma, NOS	0	1	1
	8380/3	Endometrioid adenocarcinoma, NOS	0	1	1



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2025					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C54-C55	Endometrium		0	68	68
C541	8000/3	Neoplasm, malignant	0	2	2
	8010/3	Carcinoma, NOS	0	7	7
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	5	5
	8310/3	Clear cell adenocarcinoma, metastatic, NOS	0	1	1
	8380/3	Endometrioid adenocarcinoma, NOS	0	31	31
	8380/6	Endometrioid adenocarcinoma, metastatic, NOS	0	3	3
	8441/3	Serous cystadenocarcinoma, NOS	0	5	5
	8441/6	Serous cystadenocarcinoma, metastatic, NOS	0	3	3
	8800/3	Sarcoma, NOS	0	1	1
	8980/3	Carcinosarcoma, NOS	0	6	6
C549	8000/3	Neoplasm, malignant	0	1	1
C55	8890/3	Leiomyosarcoma, NOS	0	1	1
	8931/3	Endometrial stromal sarcoma, low grade	0	1	1
C56	Ovary		0	55	55
C56	8000/3	Neoplasm, malignant	0	1	1
	8000/3	Neoplasm, malignant	0	1	1
	8010/3	Carcinoma, NOS	0	6	6
	8010/6	Carcinoma, metastatic, NOS	0	6	6
	8073/6	Squamous cell carcinoma, spindle cell, metastatic	0	1	1
	8140/3	Adenocarcinoma, NOS	0	3	3
	8140/6	Adenocarcinoma, metastatic, NOS	0	9	9
	8310/3	Clear cell adenocarcinoma, NOS	0	4	4
	8310/6	Clear cell adenocarcinoma, metastatic, NOS	0	4	4
	8380/3	Endometrioid adenocarcinoma, NOS	0	6	6
	8380/6	Endometrioid adenocarcinoma, metastatic, NOS	0	1	1
	8441/3	Serous cystadenocarcinoma, NOS	0	4	4
	8441/6	Serous cystadenocarcinoma, metastatic, NOS	0	3	3
	8480/3	Mucinous adenocarcinoma	0	2	2
	9060/3	Dysgerminoma	0	1	1
	9064/3	Germinoma	0	1	1
	9071/3	Yolk sac Tumor	0	1	1
	9071/6	Yolk sac Tumor, metastatic	0	1	1
C60	Malignant neoplasm of penis		2	0	2
C600	8071/3	Squamous cell carcinoma, keratinizing, NOS	1	0	1
C602	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1



TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2025					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C61	Prostate gland		117	0	117
C61	8000/3	Neoplasm, malignant	1	0	1
	8140/3	Adenocarcinoma, NOS	94	0	94
	8140/6	Adenocarcinoma, metastatic, NOS	22	0	22
C62, C63	Malignant neoplasm of testis		7	1	8
C620	9061/3	Seminoma	1	0	1
C621	9064/3	Germinoma	1	0	1
C629	8000/3	Neoplasm, malignant	1	0	1
	8000/3	Neoplasm, malignant	1	0	1
	9061/3	Seminoma	1	0	1
	9064/3	Germinoma	1	1	2
	9064/6	Germinoma, metastatic	1	0	1
C64 - C66	Kidney, renal pelvis & ureter		27	14	41
C64	8000/3	Neoplasm, malignant	1	0	1
	8000/3	Neoplasm, malignant	1	1	2
	8010/3	Carcinoma, NOS	3	0	3
	8010/6	Carcinoma, metastatic, NOS	1	1	2
	8130/3	Papillary transitional cell carcinoma	0	1	1
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
	8246/3	Neuroendocrine carcinoma, NOS	0	1	1
	8310/3	Clear cell adenocarcinoma, NOS	3	1	4
	8312/3	Renal cell carcinoma, NOS	11	5	16
	8312/6	Renal cell carcinoma, metastatic, NOS	3	2	5
	8313/3	Clear cell adenocarcinofibroma	1	0	1
	8317/3	Renal cell carcinoma, Chromophobe type	0	1	1
	9312/3	Odontogenic myxoma	1	0	1
C65	8120/6	Transitional cell carcinoma, metastatic, NOS	1	0	1
C66	8010/3	Carcinoma, NOS	0	1	1
C67	Bladder		26	14	40
C670	8010/3	Carcinoma, NOS	1	0	1
	8120/3	Transitional cell carcinoma, NOS	1	1	2
	8130/3	Papillary transitional cell carcinoma	2	1	3
	8130/6	Papillary transitional cell carcinoma, metastatic	0	1	1
C671	8130/3	Papillary transitional cell carcinoma	1	2	3
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
C672	8050/3	Papillary carcinoma, NOS	0	1	1
	8120/3	Transitional cell carcinoma, NOS	1	0	1
	8130/3	Papillary transitional cell carcinoma	2	1	3
C674	8120/6	Transitional cell carcinoma, metastatic, NOS	1	0	1
	8130/3	Papillary transitional cell carcinoma	1	0	1



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2025					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C675	8120/6	Transitional cell carcinoma, metastatic, NOS	1	0	1
C678	8120/3	Transitional cell carcinoma, NOS	2	1	3
	8130/3	Papillary transitional cell carcinoma	1	0	1
C679	8010/3	Carcinoma, NOS	1	1	2
	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8120/3	Transitional cell carcinoma, NOS	2	0	2
	8130/3	Papillary transitional cell carcinoma	7	3	10
	8130/6	Papillary transitional cell carcinoma, metastatic	2	0	2
C69, C70	Eye & Meninges		3	2	5
C690	8070/3	Squamous cell carcinoma, NOS	1	0	1
C695	8010/3	Carcinoma, NOS	1	0	1
C696	8010/3	Carcinoma, NOS	0	1	1
	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	1	1
C71, C72	Brain		14	4	18
C717	9400/3	Astrocytoma, NOS	1	0	1
C719	8000/3	Neoplasm, malignant	2	0	2
	8000/3	Neoplasm, malignant	1	0	1
	8010/3	Carcinoma, NOS	0	1	1
	8246/3	Neuroendocrine carcinoma, NOS	1	0	1
	8380/3	Endometrioid adenocarcinoma, NOS	1	0	1
	9380/3	Glioma, malignant	7	2	9
	9470/3	Medulloblastoma, NOS	1	0	1
	9530/3	Meningioma, malignant	0	1	1
C73	Thyroid		22	84	106
C717	9400/3	Astrocytoma, NOS	1	0	1
C719	8000/3	Neoplasm, malignant	2	0	2
	8000/3	Neoplasm, malignant	1	0	1
	8010/3	Carcinoma, NOS	0	1	1
	8246/3	Neuroendocrine carcinoma, NOS	1	0	1
	8380/3	Endometrioid adenocarcinoma, NOS	1	0	1
	9380/3	Glioma, malignant	7	2	9
	9470/3	Medulloblastoma, NOS	1	0	1
	9530/3	Meningioma, malignant	0	1	1



TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2025					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C74	Malignant neoplasm of adrenal gland		6	3	9
C740	8010/3	Carcinoma, NOS	1	0	1
C741	8700/3	Pheochromocytoma, NOS	1	0	1
C749	8246/3	Neuroendocrine carcinoma, NOS	1	0	1
	8246/6	Neuroendocrine carcinoma, metastatic, NOS	0	1	1
C75	Malignant neoplasm of other endocrine glands and relate structures				
C751	9531/3	Meningothelial meningioma	0	1	1
C753	8000/3	Neoplasm, malignant	1	0	1
C755	8000/3	Neoplasm, malignant	1	0	1
	9490/3	Ganglioneuroblastoma	0	1	1
C759	8246/3	Neuroendocrine carcinoma, NOS	1	0	1
C76 - C80	Malignant neoplasm of ill-defined, secondary & unspecified sites		2	0	2
C770	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C809	8070/3	Squamous cell carcinoma, NOS	1	0	1
C81	Hodgkin's disease		8	3	11
C81	9650/3	Hodgkin lymphoma, NOS	5	0	5
	9650/6	Hodgkin lymphoma, metastatic, NOS	1	0	1
C811	9650/3	Hodgkin lymphoma, NOS	0	1	1
C819	9650/3	Hodgkin lymphoma, NOS	1	2	3
	9650/6	Hodgkin lymphoma, metastatic, NOS	1	0	1
C82 - C88	Non-Hodgkin's lymphoma		43	37	80
C82	9695/3	Follicular lymphoma, grade 1	1	0	1
C826	9708/3	Subcutaneous panniculitis-like T-cell lymphoma	1	0	1
C827	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	0	1	1
C829	9695/3	Follicular lymphoma, grade 1	0	1	1
C830	9680/6	Malignant lymphoma, large B-cell, diffuse, metastatic, NOS	1	0	1
C833	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	10	12	22
	9680/6	Malignant lymphoma, large B-cell, diffuse, metastatic, NOS	3	3	6
C837	9680/6	Malignant lymphoma, large B-cell, diffuse, metastatic, NOS	1	0	1
	9827/3	Adult T-cell leukemia/lymphoma	1	0	1
C838	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	1	0	1
	9680/6	Malignant lymphoma, large B-cell, diffuse, metastatic, NOS	1	0	1
C840	8000/3	Neoplasm, malignant	1	0	1
	9708/3	Subcutaneous panniculitis-like T-cell lymphoma	1	1	2
	9827/3	Adult T-cell leukemia/lymphoma	1	0	1



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2025					
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C844	9702/3	Mature T-cell lymphoma, NOS	2	2	4
	9702/6	Mature T-cell lymphoma, metastatic, NOS	1	0	1
	9827/6	Adult T-cell leukemia/lymphoma, metastatic	0	1	1
C845	9827/3	Adult T-cell leukemia/lymphoma	1	0	1
C85	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	0	1	1
C851	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	1	0	1
	9596/6	Composite Hodgkin and non-Hodgkin lymphoma, metastatic	1	0	1
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	1	1	2
	9680/6	Malignant lymphoma, large B-cell, diffuse, metastatic, NOS	0	1	1
C852	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	0	1	1
C859	8000/3	8000/3	1	0	1
	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	7	5	12
	9596/6	Composite Hodgkin and non-Hodgkin lymphoma, metastatic	2	0	2
	9680/6	Malignant lymphoma, large B-cell, diffuse, metastatic, NOS	0	1	1
C860	9719/3	NK/T-cell lymphoma, nasal and-type	0	1	1
C865	9705/3	Angioimmunoblastic T-cell lymphoma	0	1	1
C884	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	0	1	1
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	0	1	1
	9699/3	Marginal zone B-cell lymphoma, NOS	3	1	4
	9751/3	Langerhans cell histiocytosis, NOS	0	1	1
C90	Multiple myeloma & malignant plasma cell neoplasms		20	15	35
C900	9732/3	Multiple myeloma	20	15	35
C91 - C95	Leukemia		35	26	61
C910	9732/3	Multiple myeloma	1	0	1
	9835/3	Precursor cell lymphoblastic leukemia, NOS	6	2	8
C911	9523/6	Olfactory neuroepithelioma	0	1	1
	9823/3	B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma	3	0	3
C920	8140/3	Adenocarcinoma, NOS	0	1	1
	9861/3	Acute myeloid leukemia, NOS	14	14	28
C921	9861/3	Acute myeloid leukemia, NOS	1	1	2
	9863/3	Acute promyelocytic leukemia, t(15;17) (q22; q11-12)	3	4	7
C924	9861/3	Acute promyelocytic leukemia, t(15;17) (q22; q11-12)	1	0	1
	9866/3	Acute promyelocytic leukemia, t(15;17) (q22; q11-12)	1	0	1
C931	8000/3		0	1	1
C944	9863/3	Acute promyelocytic leukemia, t(15;17) (q22; q11-12)	1	0	1
C946	9987/3	Therapy-related myelodysplastic syndrome, NOS	2	0	2
C950	9801/3	Acute leukemia, NOS	1	0	1
	9826/3	Burkitt cell leukemia	0	1	1
	9835/3	Precursor cell lymphoblastic leukemia, NOS	0	1	1
	9861/3	Acute myeloid leukemia, NOS	1	0	1
Total			838	898	1736



NEW CANCER PATIENTS 2021-2025

TABLE 66 NUMBER OF NEW CANCER PATIENTS : 2021 – 2025							
Years	New patient	New cancer case		Male		Female	
	Number	Number	Percent	Number	Percent	Number	Percent
2564 (2021)	46,210	1,526	3.30	771	1.67	755	1.63
2565 (2022)	47,768	1,702	3.56	822	1.72	880	1.84
2566 (2023)	41,671	1,825	4.38	912	2.19	913	2.19
2567 (2024)	44,300	1,924	4.34	944	2.13	980	2.21
2568 (2025)	41,522	1,736	4.18	838	2.02	898	2.16
Total	221,471	8,713	19.77	4,287	9.73	4,426	10.04

TABLE 67 DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP AND GENDER: 2021-2024						
Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	2422	56.5	3137	70.9	5559	63.8
Deaths	1865	43.5	1289	29.1	3154	36.2
Total	4287	100.0	4426	100.0	8713	100.0

Survey: 1 May 2026



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2025

TABLE 68 THE LEADING PRIMARY SITES OF NEW CANCER BY GENDER: 2021-2024							
Ordinal	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
1	Colon & Rectum	674	15.7	485	11.0	1159	13.3
2	Breast	13	0.3	1034	23.4	1047	12.0
3	Bronchus & Lung	531	12.4	434	9.8	965	11.1
4	Prostate gland	617	14.4	0	0.0	617	7.1
5	Thyroid	119	2.8	480	10.8	599	6.9
6	Liver & intrahepatic bile ducts	415	9.7	129	2.9	544	6.2
7	Digestive organ	274	6.4	156	3.5	430	4.9
8	Non-Hodgkin's lymphoma	213	5.0	177	4.0	390	4.5
9	Malignant neoplasm of lip, oral cavity & pharynx	233	5.4	103	2.3	336	3.9
10	Endometrium	0	0.0	268	6.1	268	3.1
Others		1198	27.9	1160	26.2	2358	27.1


TABLE 69 THE LEADING PRIMARY SITES OF NEW CANCER BY FOLLOW UP AND GENDER: 2021-2024						
Ordinal	Primary site	Alive		Deaths		Total
		Male	Female	Male	Female	
1	Colon & Rectum	429	307	245	178	1159
2	Breast	10	880	3	154	1047
3	Bronchus & Lung	185	206	346	228	965
4	Prostate gland	501	0	116	0	617
5	Thyroid gland	109	463	10	17	599
6	Liver & intrahepatic bile ducts	132	49	283	80	544
7	Digestive organ	85	65	189	91	430
8	Non-Hodgkin's lymphoma	133	117	80	60	390
9	Malignant neoplasm of lip, oral cavity & pharynx	124	68	109	35	336
10	Endometrium	0	217	0	51	268
Others		714	765	484	395	2358



TABLE 70	THE 5 YEARS SURVIVAL TIME (MEDIAN) TOP 6 BY GENDER IN 2021 - 2025		
Ordinal	Primary site	Male	Female
1	Colon & Rectum	19.88	21.25
2	Breast	41.25	29.39
3	Bronchus & Lung	10.53	15.95
4	Prostate gland	28.65	-
5	Thyroid	27.21	31.96
6	Liver & intrahepatic bile ducts	9.43	9.08

Survey: 1 May 2026

FIGURE 33: THE 5 YEARS SERVIVAL RATE (TOP 6) IN 2021 – 2025





HOSPITAL-BASED CANCER REGISTRY 2025

ANNUAL REPORT

FIGURE 34: THE 5 YEARS SURVIVAL RATE (TOP 6) BY MALE IN 2021 – 2025








FIGURE 35: THE 5 YEARS SURVIVAL RATE (TOP 6) BY FEMALE IN 2021–2025



Phramongkutklao Hospital 315 Ratchawithi Rd, Bangkok 10400 Thailand.



PHRAMONGKUTKLAO HOSPITAL

EXCELLENT CENTER
OF CANCER CARE

2025

Oncology Unit and Epidemiology Unit,
Phramongkutklo Hospital.

315 Ratchawithi Road, Bangkok 10400, Thailand.

Tel. : + 66 2763 3047

Email : ceupmk@hotmail.com

Website : <http://ceu.pmk.ac.th>